

Klinefelter syndrome - integrating genetics, neuropsychology and endocrinology

Claus H. Gravholt, Simon Chang, Mikkel Wallentin, Jens Fedder, Philip Moore and Anne Skakkebaek

Endocrine Reviews
Endocrine Society

Submitted: September 20, 2017
Accepted: February 05, 2018
First Online: February 09, 2018

Advance Articles are PDF versions of manuscripts that have been peer reviewed and accepted but not yet copyedited. The manuscripts are published online as soon as possible after acceptance and before the copyedited, typeset articles are published. They are posted "as is" (i.e., as submitted by the authors at the modification stage), and do not reflect editorial changes. No corrections/changes to the PDF manuscripts are accepted. Accordingly, there likely will be differences between the Advance Article manuscripts and the final, typeset articles. The manuscripts remain listed on the Advance Article page until the final, typeset articles are posted. At that point, the manuscripts are removed from the Advance Article page.

DISCLAIMER: These manuscripts are provided "as is" without warranty of any kind, either express or particular purpose, or non-infringement. Changes will be made to these manuscripts before publication. Review and/or use or reliance on these materials is at the discretion and risk of the reader/user. In no event shall the Endocrine Society be liable for damages of any kind arising from references to, products or publications do not imply endorsement of that product or publication.

Klinefelter syndrome

Klinefelter syndrome - integrating genetics, neuropsychology and endocrinology

Claus H. Gravholt^{1,2}, Simon Chang^{1,3}, Mikkel Wallentin^{4,5}, Jens Fedder⁶, Philip Moore⁷ and Anne Skakkebaek^{2,8}

¹Department of Endocrinology and Internal Medicine (MEA), Aarhus University Hospital, Aarhus, Denmark,

²Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark, ³Department of Clinical Biochemistry, Esbjerg Sygehus, Denmark, ⁴Department of Linguistics, Cognitive Science and Semiotics, Aarhus University, Aarhus, Denmark, ⁵Center of Functionally Integrative Neuroscience, Aarhus University Hospital, Aarhus, Denmark, ⁶Centre of Andrology and Fertility Clinic, Department of Gynaecology and Obstetrics, Odense University Hospital, Odense, Denmark, ⁷Department of Psychology, The George Washington University, Washington DC, USA, ⁸Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark.

Received 20 September 2017. Accepted 05 February 2018.

Although first identified over 70 years ago, Klinefelter syndrome (KS) continue to pose significant diagnostic challenges, as many patients are still misdiagnosed, or remain undiagnosed. In fact, as few as 25% of KS patients are accurately diagnosed, and most of these diagnoses are not made until adulthood. Classic characteristics of KS include small testes, infertility, hypergonadotropic hypogonadism, and cognitive impairment. However, the pathophysiology behind KS is not well understood, although genetic effects are also thought to play a role. For example, recent developments in genetics and genomics point to a fundamental change in our understanding of KS, with global epigenetic and RNA expression changes playing a central role for the phenotype.

KS is also associated with more general health markers, including higher morbidity and mortality rates, and lower socio-economic status (which likely affects both morbidity and mortality). In addition, hypogonadism is associated with greater risk of metabolic syndrome, type 2 diabetes, cardiovascular disease, breast cancer, and extragonadal germ cell tumors. Medical treatment typically focuses on testosterone replacement therapy (TRT), although the effects of this therapy has not been studied rigorously, and future studies need to evaluate the effects of TRT on metabolic risk and neurocognitive outcomes.

This review presents a comprehensive, interdisciplinary examination of recent developments in genetic, endocrine and neurocognitive science, including the study of animal models regarding KS. It also provides a number of recommendations for improving the effectiveness of research and clinical practice, including neonatal KS screening programs, and a multidisciplinary approach to KS treatment from childhood until senescence.

Essential points:

1. Identification of KS is more difficult than previously anticipated, with only a fraction (25-40%) of cases accurately diagnosed. This has broad implications for the interpretation of research literature and the effectiveness of clinical practice. More accurate KS diagnoses are unlikely with current clinical approaches, and we suggest incorporation of KS in neonatal screening programs.
2. KS is associated with a globally changed DNA methylation profile, with large areas of hypermethylation and, to a lesser degree, hypomethylation. More subtle differential RNA expression extending far beyond the supernumerary X chromosome is also present. These findings suggest the importance of linking phenotypical and genotypical components of KS.
3. Morbidity and mortality is increased from a wide variety of diagnoses, many that are not easily reconciled to the known KS phenotype or effects of hypergonadotropic hypogonadism. Poor socioeconomic status explains part of the increased morbidity and mortality.

4. Although hypogonadism is among the classic characteristics of KS, the effects of testosterone replacement therapy is not well studied, and many questions concerning timing, dose, and route of administration remain to be answered.
5. KS patients also experience pervasive neurocognitive deficits, which pose additional challenges for individuals with KS. Neurocognitive therapy may be helpful in many of these cases.
6. Multidisciplinary clinics should be the mainstay throughout the world in clinics treating those with KS. This should improve the quality and consistency of care from childhood through adolescence, and into adulthood.

Klinefelter syndrome (KS) still pose diagnostic challenges and many remain undiagnosed. Here we review new aspects of the syndrome and integrate genetics, neurocognition and endocrinology.

1. Introduction

Klinefelter syndrome (KS), 47,XXY, occurs in 150 per 100,000 live born males (1). No universal agreement exists in the scientific community on the exact definition of KS, but in addition to possessing one or more extra X chromosomes, KS males typically exhibit phenotypical traits that include hypergonadotropic hypogonadism, testosterone deficiency, and infertility (2). Phenotypic variability, however, often leads to diagnostic delay or non-diagnosis, with an estimated 50-75% of males with KS never obtaining correct diagnosis (1;3). KS can have profound adverse consequences, as morbidity and mortality among known KS males is significantly higher than in the general population (4-9), and these health risks are presumably even higher among those KS males who never receive testosterone replacement therapy (TRT) by virtue of not being correctly diagnosed. The key to more timely diagnosis and treatment of KS is a more comprehensive understanding of its etiology, characteristics and effects, which is the goal of this review.

Risk assessment in KS is compromised by insufficient insight into the prevalence and causes of different syndrome-associated traits that may impact adversely on prognosis. This is especially the case for genetic, endocrine, cardiovascular, neurocognitive and behavioural contributions to the wide range of diseases, that together contribute to excess all-cause mortality (10). Since late diagnosis and non-diagnosis is frequent, ascertainment bias may obscure the epidemiological picture of many KS aspects, and current attempts at providing guidelines may well underestimate both morbidity and mortality. Previous guidelines and reviews have all relied on expert consensus and have not included a broad base of professionals working with KS (2;11-13). This is unfortunate because complex patterns of both endocrine, psychiatric and other diseases in KS render direct translation of evidence from other cohorts hazardous. More educated risk stratification and more appropriate clinical care can only be facilitated through a thorough delineation of the phenotype in KS.

This review provides specific insights into the genetic, endocrine, metabolic, cardiovascular and neurocognitive phenotype in males with KS, and presents an up-to-date synopsis of the latest body of knowledge, emphasizing the significance of both congenital and acquired pathologies. The aim is to provide an update on current insight into the pathogenesis of KS and relate to recent advances in the understanding of the dosage effect of having an extra X-chromosome, exposure to X-inactivation, and its influence on male health. Moreover, this review provides an updated hypothesis on the genetic etiology of KS, highlighting our knowledge about importance of X-chromosomal aneuploidy to congenital and acquired neurocognitive and endocrine traits. Finally, this review incorporates important endocrine features of KS, accounting for how genetics may explain the prevailing phenotype, and how attention to endocrine factors is important in efforts to identify and modify risk markers. Where available, data from animal models are included. We conclude with perspectives on where science may take us in the future.

The full PubMed database was searched (without time restrictions) in May 2017 using the keyword “Klinefelter syndrome” as MeSH term, as well as “Klinefelter syndrome”, “Klinefelter’s syndrome”, “Klinefelter”, “Klinefelter’s” in titles and abstracts. Articles relevant to the individual topics were obtained and reviewed, as well as older articles selected by the authors. Publications cited in this review were selected from those identified by the searches at the authors’ discretion.

2. Prevalence, morbidity and mortality

When KS was first described by Harry F. Klinefelter, Edward C. Reifenstein and Fuller Albright in Boston in 1942 (14) the authors described the occurrence of the syndrome as “not uncommon”. When Patricia A. Jacobs and John A. Strong in 1959 described the karyotype, 47,XXY, it became possible to verify the diagnosis by standard karyotyping and thus to examine large populations (15). However, although many surveys of newborns subsequently have been performed, it is still not clear how frequent KS is, and especially whether there are demographic differences in prevalence. It is nonetheless clear that diagnosis and especially late or non-diagnosis of the syndrome is of significant concern. Few boys with KS are diagnosed, and only a minority of the expected number is diagnosed during adulthood (1). Non-diagnosis may likely introduce ascertainment bias and hamper the interpretation of the current literature on KS. Are non-diagnosed KS males similar to diagnosed KS? Are they much less affected with no or few symptoms, which could explain the conundrum of non-diagnosis, or are they more severely affected leading to premature death before diagnosis? In this section, all aspects of epidemiology will be discussed, and areas of uncertainty will be highlighted.

2.1 Prevalence

Based on a number of large cytogenetic chromosome surveys of newborns in various countries around the world, it is possible to compute an estimate of the average prevalence of KS at birth, which is 152 per 100,000 newborn males [95% confidence interval (CI), 121–188 per 100,000] (a total of 84 diagnosed with KS in 55,212 boys), ranging from 85–223 per 100,000 males (16–23). Still, these studies were all performed primarily with Caucasian and Japanese individuals. More recent research in Denmark, Australia and USA (3;24;25) has replicated these results, along with showing a significant diagnostic divergence dependent on the time of diagnosis. In Denmark, we determined the prevalence of KS based on prenatal examination to be 153 (145–161) per 100,000 liveborn males, which is very close to previous estimates (1), and since spontaneous abortions rarely occur (24), this prevalence can be seen as a valid index of prevalence in Denmark. The prevalence based on postnatal examination, however, was much lower, and for the entire study period from 1931–2000 only 28 per 100,000 KS were detected, which illustrates low diagnostic yield in the beginning of the 20th century. But even so, it is clear that many KS males are not diagnosed, and we estimated that only about 25% of all KS were diagnosed postnatally. In a study from Australia, a somewhat higher pre- and postnatal prevalence of 223 (195–254) per 100,000 and 87 (70–107) per 100,000 was presented (3), indicating that about 40% of the expected KS males were diagnosed postnatally. The authors speculate that the higher pre- and postnatal prevalence in Australia compared with Denmark may be due to the combined effect of older Australian mothers and a different racial composition of the Australian populace. A recent study from USA suggested that the prevalence of KS among males with white ethnicity was 166 per 100,000, but 355 per 100,000 among males with Asian ethnicity, although numbers in this study were small (25).

2.2 Diagnosis and non-diagnosis

The diagnosis of a male with KS rests on clinical appearance coupled with a karyotype of 47,XXY or mosaics thereof. There is no universal agreement on the necessary clinical signs or stigmata that should lead to karyotyping (2;26). We believe that persons with additional sex chromosomes (48,XXXY, 48,XXYY and other similar syndromes) should not be considered KS, because they normally have a much more affected phenotype (27). The cardinal stigmata include small testes (which are present in virtually all KS), hypergonadotropic hypogonadism, gynecomastia, learning difficulties and infertility. It is clear though, that many other signs, symptoms and conditions can be associated with KS (Table 1). However, absence of overt clinical signs is often the case, and many males with KS are difficult to distinguish from the normal 46,XY male (28;29). As mentioned above, epidemiological studies have estimated the diagnostic yield in different countries. It seems that only 25-40% of the pool of KS are ever diagnosed (1;3;30), and only about 10% of these are diagnosed during childhood and adolescent years, while the bulk of patients are diagnosed during adulthood, typically in the course of a fertility workup (3), as shown in these updated Danish data (Figure 1), which found a mean age at diagnosis of 27 years. It can be seen from these new data that 65% of prenatally diagnosed KS are legally aborted, that only a small fraction is diagnosed in childhood, and that a minority are diagnosed quite late in life after the age of 50 years. A British study on mortality in KS found 3518 individuals with KS ever diagnosed by the year 2000, and one can indirectly make a crude estimate of the prevalence to 11.9 per 100,000 males (UK population (2000): 58.89 million, estimated male population: 29.45 million)(4). Likewise, a recent Swedish study on cancer epidemiology found 1085 individuals with KS, and one can estimate a prevalence of 23.1 per 100,000 males (Swedish male population (2010): 4.69 million)(6), which shows that far fewer KS males are diagnosed in Great Britain and Sweden than would be expected. These crude estimates do not adjust for the somewhat elevated mortality rate which is present among KS (4;5;8;10), but even so, they illustrate that the diagnostic yield maximally reaches 40% of the expected number in all countries with available nationwide data. These figures beg the question of why so many KS are not diagnosed. KS can be diagnosed prenatally by amniocentesis, chorion villus sampling or cell-free DNA testing (31). Furthermore, Down syndrome screening using UL-based nuchal fold measurement, serum pregnancy-associated protein A and free beta human chorionic gonadotropin detect 19 KS per 100,000 males fetuses (13% of the expected number) (24). Evaluation of all available studies from a wide range of countries shows that about 44-85% of parents choose legal abortion of a KS fetus (24;32), reducing the number of liveborn KS, but only marginally due to the low level of detection of KS by prenatal methodology. Applying the legal abortion rate to KS prevalence found in our previous studies, legal abortion in Denmark at the present would be expected to reduce the prevalence of liveborn KS from 150 to 140 per 100,000 males (1;24). This may well change in the future with optimization of especially cell-free DNA testing leading to detection of much greater numbers of KS, given parents will continue to choose legal abortion with a rate of 45-85% (24;32). Taken together, available data show that diagnosis of KS is often seriously delayed, and frequently a diagnosis is never made (30), illustrating that new diagnostic avenues should be implemented. Late diagnosis or non-diagnosis extend to all sex chromosome syndromes (33-36). We, and others, have called for population-based, neonatal genetic screening to clarify several questions concerning prevalence and phenotypic spectrum and enabling early establishment of appropriate treatment (37-39). Population-based, neonatal screening can be considered if a condition is an important health problem with a latent, early asymptomatic stage, has a well-understood natural history, and for which there are accepted treatments with associated facilities for diagnoses and treatment (40). We think that these requirements are fulfilled for KS, although due to the rarity of the syndrome, it will likely take a long time to

demonstrate associations between early diagnosis, continuous specialized care and improved long-term outcomes.

2.3 Morbidity

The morbidity pattern among KS males is diverse (Figure 2), which is difficult to reconcile with the different phenotypic characteristics usually present among KS males, including hypergonadotrophic hypogonadism, infertility and neuro-cognitive deficits. We investigated the Danish registries regarding the morbidity pattern in KS and found an elevated morbidity for almost all ICD-10 chapters (except the chapter “diseases in the newborn”) (9). Infections, certain cancers (breast and mediastinal), anemia, psychiatric diseases (psychoses, neuroses/personality disorders, mental retardation), neurological diseases, circulatory diseases (ischemic heart disease, deep venous thrombosis, lung embolia)(7), pulmonary diseases (pneumonia, chronic obstructive pulmonary disease, asthma), gastrointestinal disease (ulcus, cirrhosis of liver), skin diseases, diseases of the musculoskeletal system (osteoarthritis), diseases of the urogenital system (infections, gynecomastia), congenital malformations (heart, genitalia, retention of the testis), trauma and intoxications were all seen significantly more among KS. Endocrine diseases were as well seen more frequently among KS, including type 1 diabetes, type 2 diabetes, hypogonadism and hypothyroidism. At that time, some of these diseases had previously been associated with KS, but many had not. This applied to conditions like pneumonia, chronic obstructive pulmonary disease, asthma, osteoarthritis, ulcus etc., likely due to their commonality in the general population.

The pattern of malignant disease in KS shows that although the risk of cancer in general is close to that of the normal male population (5;6;9), certain patterns emerge with a higher risk of breast cancer, mediastinal tumor, non-Hodgkin lymphoma and haematological cancers in general, while the risk of prostate cancer is low. It remains unexplained why some cancers are more frequent among KS, but a genetic background seems plausible. On the other hand, it is likely that the scarcity of prostate cancers is due to low levels of endogenous testosterone in the untreated condition, and/or undertreatment with testosterone, and thus relative hypogonadism among many KS. A recent large study of non-KS in UK pointed towards increased body fat and presence of diabetes as protective risk markers (41), which also could be at play in KS.

Such a pattern of morbidity points to other factors than just hypogonadism, genetic causes and decreased neuro-cognitive deficits as explanatory factors, and we have extended our register studies and included socio-economic variables accordingly. In a recent study, we show that the socio-economic status of KS males is very different from that of controls. Less than 10% KS achieve a higher education, while retirement age on average is more than 15 years earlier (KS versus controls: 43.5 vs 60.3 years). Fewer KS become fathers, and more live alone (10). As a result, the annual income throughout the lifespan is much lower among KS. The reduced socio-economic status that emerges is undoubtedly an explanatory factor for the diverse morbidity pattern, as shown in other settings (42), but we still need to untangle the additive effects of the syndrome per se, late diagnosis, undertreatment of hypogonadism and possibly also inadvertent overtreatment with exogenous testosterone.

2.4 Mortality

All studies of mortality rates among KS have found this to be greater than among matched controls or the general population (4;8;10;43). The same is seen among other sex chromosome abnormality syndromes, such as Turner syndrome (44;45), 47,XXX (34;46) and 47,XYY (35;43). This seems to be an intrinsic consequence of sex chromosome aneuploidy and as such a common trait, which comparative analyses point towards (43;46). In our latest published analysis we have estimated that mortality among KS is increased with a hazard ratio of 1.9, which corresponds to median loss of 5.6 years (10). The excess mortality among

KS follows the pattern from the morbidity data and is a result of a wide range of diseases, including diseases of the circulatory, respiratory, endocrine and metabolic systems, and of cancer (Figure 3). The increased risk of death among KS may partially be explained by their lower socioeconomic status (10). An updated analysis of the total cohort of KS males in Denmark (Figure 1) - including all diagnosed until December 2016 – shows an overall mortality hazard ratio (HR) of 1.63 (1.45-1.83, $p < 0.05$). Moreover, HR before 30 years of age is 4.18 (2.72-6.40) and HR before 15 years of age 9.56 (4.40-20.76). These estimates show that especially KS diagnosed at an early age have a very high mortality relative to age-matched controls. We currently do not understand the basis for this elevated mortality, but we speculate that the cohort constituting the young group of diagnosed KS has a much more complicated phenotype, which leads to early diagnosis in the first place and thus a higher mortality.

Summary of best evidence

The prevalence of KS range from 85 to 250 (-355) per 100,000 liveborn males, and it is possible that there are ethnic differences. Only a minority (25-40%) of the expected number KS males are ever diagnosed. Morbidity and mortality is increased across all diagnostic chapters, with likely influences from hypogonadism, genetic factors, poor socioeconomic conditions and perhaps also from TRT.

Areas of controversy

There is a dire need for population-based studies in different ethnic groups, both to establish a valid and reliable prevalence and to assess the impact of ethnicity. It is currently not clear how to improve the diagnostic yield in the best way. We advocate for the introduction of population-based neonatal screening, although the cost-benefit ratio of such an initiative has yet to be evaluated. It is not clear how TRT impacts the general pattern of morbidity and mortality as well as specific diseases.

3. Genetics of Klinefelter syndrome

Neither the origin nor the phenotypic manifestation of sex chromosome abnormalities is well-understood, and phenotypic features consistently associated with these syndromes remain elusive (47). Other than KS, sex chromosome syndromes include Turner syndrome (45,X), 47,XXX syndrome and 47,XYY syndrome. The current understanding of the X and Y chromosomes is based on evolutionary research; the sex chromosomes evolved from an identical pair of autosomes, but while the X chromosome has retained most of the original genes (649 genes), the Y chromosome retained only about 40 genes of which 17 are shared with the X chromosome. These mutual genes are involved in regulating other genes throughout the entire genome (47). Bellott et al. showed that 12 of the remaining genes on the Y chromosome, having identical haplotypes on the X chromosome, are needed in exactly two copies, and thus might play a vital role in sex chromosome abnormalities (1).

The overarching biological question related to sex chromosome abnormalities is how to merge the understanding of the genome, epigenome, transcriptome e.g., with the different phenotypic manifestations related to different organs, viability, occurrence of congenital malformations, e.g. Similarly, traits as severe and diverse as type 2 diabetes, intrauterine demise, congenital cardiovascular malformations and altered neurocognitive performance remain largely unexplained. Very recent studies with a system biology approach suggest an increased X chromosome gene dosage linked with altered protein interactome activity as an explanation for the observed comorbidities among KS (48). The authors have epidemiologically mined a patient registry, merged with RNA expression data and exploited protein-protein interaction databases, to discover altered Jak-STAT signalling, dysregulated

genes involved in immune system function, energy balance (POMC and LEP), and erythropoietin signalling, to be present in complex comorbidity networks in KS (48).

3.1 Genotype-phenotype associations

Despite comprehensive research, our knowledge about the genotype-phenotype relation in KS is limited. Genetic mechanisms related to the X chromosome as well as the androgen receptor have been evaluated for a possible impact on the phenotype in KS. These genetic mechanisms include the parental origin of the supernumerary X chromosome, the pattern of X chromosome inactivation and the androgen receptor CAG repeat length.

The 47,XXY karyotype arises from non-disjunction, either as a paternal nondisjunction in the first meiotic division (50% of cases), or as maternal nondisjunction in first or second meiotic division or during post-zygotic division (50% of cases) (49;50). The possibility that the parental origin of the extra X chromosome should have an impact on the phenotype has been proposed. The evidence is sparse however, with the majority of studies finding no association (51-54), and only few finding a parental-origin-effect on phenotypic traits including motor function and language/speech (55), autistic and schizotypal traits (56), onset of puberty (57) and waist and height to arm span ratio (29).

In KS as in females, one of the two X chromosomes is inactivated early in embryogenesis – a process that normally occurs randomly (58). However, evidence suggests that skewed inactivation of the X chromosomes (>80% inactivation of one of the allele) occur in up to 43% of patients with KS (59). Skewed X chromosome inactivation may result in a silencing of either maternally or paternally imprinted genes, and it has been posited that some of the phenotypic variability in KS may be caused by this mechanism. However, the research to date does not support this hypothesis (29;51;52;54;60-62).

Polymorphism in the CAG repeat length in exon 1 of the androgen receptor gene has also been investigated for its relation to the phenotypic variability seen in KS, as the length of the CAG repeat is negatively correlated with the function of the androgen receptor (63). The existing literature shows that CAG repeat length of the androgen receptor does explain some of the variability seen in the phenotype of patients with KS, especially concerning anthropometry, with a positive correlation with height (60;62), arm span (29;60;62), arm length (29), and leg length (29). Concerning other anthropometric measurements, however, such as bitesticular volume and gynecomastia (29;62), as well as data regarding haematology (29;60;62), lipid metabolism (29;60) and bone related parameters (60;62), the findings are more inconsistent with some studies finding a negative correlation between these measurements and CAG repeat length, while others found no correlation. Regarding cognitive function, no associations to CAG repeat length have been reported (51;52). An association between CAG repeat length and response to testosterone therapy has also been found (62), but was not supported by another study (60). In addition to these findings, individual studies have also investigated and reported an inverse correlation between CAG repeat length and penile length (54), attained educational level and chances of entering partnership (62). Wikstrom et al. also found an inverse correlation between CAG repeat length and later onset of pubertal reactivation of the pituitary gonadal axis (57), which fits well with the finding of a positive correlation with height and armspan (29;60;62). Conclusively, CAG repeat length is related to different anthropometric measures and possibly also other measures, but remains a research tool. At present, it is not expected to become of manifest importance in the clinic.

Most males with KS have the karyotype 47,XXY (85-90%), while 6-7% have 46,XY/47,XXY mosaicism karyotype (1;16), and the remaining 3-8% display either 46,XX/47,XXY or multiple X chromosome aneuploidy, including some with an additional Y chromosome (47,XXY/48XXXXY, 48,XXXXY, 48,XXYY, 49, XXXXY). These latter cases display a more severe phenotype should probably be considered outside the realm of

Klinefelter syndrome diagnosis (1;16)(Figure 1). Boys and men with mosaicism have been described as presenting with a more favorable phenotype compared to non-mosaic KS (28;64), however, only one study has compared KS men with 47,XXY with KS men having 46,XY/47,XXY mosaicism (65). This study included only 6 KS men with mosaicism with the proportion of XY/XXY ranging from 2-87.5%. Here, KS men with 46,XY/47,XXY had larger testicular volume, lower level of luteinizing hormone and estradiol, higher mean total sperm count compared to non-mosaic KS (azoospermic 93.0 vs 96.3%), and none of them reported any comorbidity. Further studies are needed to characterize the phenotype of KS men with 46,XY/47,XXY. Regarding the 46,XX/47,XXY karyotype, the prevalence is very low with only 8 case reports published so far.

In addition to the above mentioned genetic mechanism related to the X chromosome, CAG repeat length and the karyotype, it has been suggested that the phenotype may be explained by X-linked escape genes, but the evidence is sparse. Thus far, only one gene on the sex chromosomes has been convincingly connected to the phenotype in KS – the *SHOX* gene – which explains some of the excess growth (66).

No genes or genetic mechanisms have been able to explain, for example, the increased risk of type 2 diabetes or attendant infertility and the cognitive and behavioral phenotype. Although the evidence for a gene dosage effect on the phenotype is largely missing, new support for this theory comes from Bellott et al. who demonstrate that several genes on the Y chromosome have identical haplotypes on the X chromosomes. These genes could in theory be involved in the phenotype since they are expressed thrice in KS. Interestingly, Bellott et al. found evidence that sex chromosomes may regulate gene expression throughout the genome due to enrichment of genes involved in transcription and translation (47), indicating that the phenotype seen in KS may be caused by a different expression of autosomal genes as well. Further evidence for this theory comes from a recent published study by Belling et al. (48) who evaluated gene expression in peripheral blood in men with KS and controls. They identified 363 differentially expressed genes in men with KS compared to controls, of which the majority was located on autosomal chromosomes. In addition, their analysis indicated dysregulation of genes involved in the immune system and energy balance, two areas associated with the phenotype in KS.

Although a gene dosage effect of having a supernumerary X chromosome may explain some of the phenotypic traits seen in KS, it cannot explain the variability seen in the clinical phenotype in KS, indicating that other mechanism plays a crucial role for the observed phenotype. Recently published data provided evidence that the DNA methylation profile in KS is associated with widespread changes both in blood and brain tissue (67;68). It is possible that these genome-wide alterations in DNA methylation play a role in the biological mechanism behind the clinical phenotype in KS, as well as its variability, as DNA methylation is part of our regulatory epigenetic machinery that is thought to affect our gene expression. More studies are needed to further elucidate these epigenetic perspectives on the phenotype, including studies of target tissues such as muscle, fat, brain and testis, including both DNA methylation analysis, RNA expression analysis, as well as proteome analysis.

We recently presented data on epigenetics and RNA expression in blood from Turner syndrome individuals, which implicates several genes not hitherto thought to be involved in the phenotype of Turner syndrome (69), and these findings may have relevance for the conceptual thinking of genetics concerning KS. We found global hypomethylation of the genome, but also areas of hypermethylation and RNA expression changes. We speculate that the widespread hypomethylation of proximal promoters may have regulatory impact on gene transcription and suggest a possible link between the differential methylation and expression seen. In this study, the sex-chromosome analysis provided the largest existing set of differentially expressed genes, and in combination, these genes can be linked to several of the

specific characteristics of Turner syndrome. They included known escape genes such as *RPS4X*, *JPX* and *LANCL3*. Other X-chromosomal genes were differentially expressed (*CD40LG* and *KDM5C*). Since *KDM5C* participates in transcriptional repression of neuronal genes, we speculate that *KDM5C* may play a role in the distinct neuro-cognitive profile of Turner syndrome. In KS, we see something resembling a mirror image of the changes in Turner syndrome, with preferential hypermethylation, but affecting many of the genes also involved in Turner syndrome. We have also found pervasive RNA expression changes involving genes throughout the genome (unpublished material). Thus, a complicated picture of genotypic effects on phenotypes in KS is beginning to emerge, with epigenetic, RNA expression and protein-protein changes. The precise impacts of these changes - and other genomic mechanisms - remain to be elucidated. A pictogram of the current understanding is presented in Figure 4.

3.2 X chromosome inactivation and influence of the extra X chromosome

Among KS, a global preferential hypermethylation of the genome seems to be present (67), although some CpG sites are hypomethylated, changes which can be thought of as orchestrated from the supernumerary X chromosome. Particularly for X-chromosome inactivation, long non-coding RNAs are known to control the histone modifications that precedes chromatin condensation and Barr body formation (70). Long non-coding RNAs regulate gene expression at many different levels, including through chromatin structure, transcriptional activation and transcript stability (71). Non-coding RNAs often function via direct sequence complementarity with target transcripts and potentially target DNA regions. The overarching biological question related to KS is how to merge the understanding of the genome, epigenome, transcriptome etc., with the different phenotypic manifestations related to different organs, viability, occurrence of congenital malformations, etc. Traits as diverse as type 2 diabetes, infertility, hypergonadotropic hypogonadism, congenital malformations, and altered neurocognitive performance remain unexplained.

Importantly, research and the thinking behind in the genomics era have moved away from focusing on single genes on the supernumerary X chromosome to explain the majority of phenotype in KS, to a focus on more subtle pervasive changes in the epigenome and transcriptome as the possible background (Figure 4).

Summary of best evidence

The presence of three copies of the *SHOX* gene explains excess height in KS and CAG repeat length is related to different anthropometric measures.

Areas of controversy

Genotype-phenotype relations in KS are largely unexplained. The current thinking that pervasive but discrete changes in the epigenome and the transcriptome explains parts of the phenotype still lacks compelling evidence. Yet other genetic mechanisms such as copy number variation or additional expression of escape genes on the extra X chromosome may be at play.

4 Hypogonadism and metabolic disease in Klinefelter syndrome

While small testes are a hallmark of KS, many KS pass through a normal or close to normal puberty without being detected. However, hypogonadism invariably presents problems sooner or later on in life.

4.1 Hypergonadotropic hypogonadism

4.1.1 Intra-uterine and childhood hypogonadism

Whether hypogonadism is already present in utero is not clear. Studies point towards an altered 2D:4D (the length of the second digit/fourth digit ratio), suggesting a relative intra-

uterine hypogonadism (29;72). Although controversial, the 2D:4D ratio has been suggested to be a surrogate marker of intra-uterine androgen exposure (73). The ano-genital distance may be a more precise measure of this, but at present there are no published data on ano-genital distance in KS. Additional evidence with microphallus, cryptorchidism, degeneration of seminiferous tubules, and hyperplasia of Leydig cells suggests that even the KS fetus may often express lower levels of testosterone compared to male fetuses with normal karyotype (74), although measurements of amniotic fluid testosterone in a small group of KS fetuses, as well infants, were similar to controls (75)(76). A study of 4-12 year olds found that a large percentage of KS children had relatively low testosterone levels and about 25% had relatively reduced penile length (77). In this same study, the authors found that elevated FSH and low inhibin B were associated with a worse metabolic profile (77), indicating that emerging testicular failure and subsequent elevation of pituitary hormones could be linked to the metabolic syndrome, which is prevalent among adults with KS (see below) (78). At the onset of puberty, which occurs at the same time as in normal youth, the testis start to enlarge (79), soon to be followed by shrinkage despite elevated levels of FSH and LH (80), and testis size then remains much smaller than among normal adult males, with an average size of 2-4 ml (normative range: 15-30 ml) (28;29).

Interestingly, a link between prenatal testosterone and adult facial features has been established, showing that a higher umbilical cord testosterone is associated with a more masculine facial structure, and that the facial morphology was seemingly unaffected by adult testosterone levels (81). It would be very interesting to see if the intrauterine hormonal milieu is also revealed in the faces of KS boys and men.

4.1.2 Adulthood

Studies of adults with KS generally describe hypogonadism as being present in most males, but many KS in fact have testosterone levels within normative ranges, and only when incorporating an elevated level of LH does a picture of compensated or relative hypogonadism emerge (82). The overwhelming majority of males with KS in outpatient clinics fulfills the criteria for hypogonadism (28;29;62).

Data from animal studies

In the two available mouse models of KS, testis weight is much smaller than in littermates (83;84), while circulating testosterone was only significantly lower in aged KS mice (41,XX^{Y*})(84), seminiferous tubules were small and Sertoli cell-only with absence of germ cells, and Leydig cell hyperplasia was present (83;84), largely emulating human data.

Summary of best evidence

Data indicate that many KS may be afflicted by relative hypogonadism much earlier in life than has previously believed, and that hypogonadism is present long before the testosterone concentration irreversibly level off around mid-puberty.

Areas of controversy

There is need for large long-term follow-up studies of children with KS in order to determine the natural history of hypogonadism.

4.2 Weight and body composition

One obvious reason for the low rate of diagnosis in KS is the lack of immediately recognizable physical features. Unlike the altered physical traits in autosomal trisomy, as in Down syndrome, only subtle changes in physiognomy are found in KS, although small, soft testes that differs in quality to normal testes, are an unequivocally described trait in KS populations (Table 1). Typically, adult bitesticular volume is less than 10 mL with a mean around 4-7 mL (29;85). However, in our experience, palpation of the scrotum is not routinely carried out in the male population, and even when small testes are in fact palpated, the possibility of KS is often not taken into consideration, which could be due to lack of

knowledge about KS among physicians. Also, in pre-adolescent and adolescent KS, the difference in testicular volume between KS and normal males is less pronounced, although present (86).

Height in KS is increased with a mean of 5-7 cm compared with normal men (29;87). However, the variability in height in KS is similar to normal men. The increased height is mainly based on an increased leg length (29), likely caused by delayed epiphyseal closing due to relative pubertal hypogonadism. The same mechanism also causes a relatively large arm span, sometimes exceeding height (29;88). Increased height, however, has also been demonstrated already at ages 4-12 in KS boys (89), well before normal epiphyseal fusion, pointing towards an effect of other modulators, such as for instance *SHOX* gene dosage and increased number of CAG-repeats in the androgen receptor (29;60;62).

In the original description of the syndrome, gynecomastia was found in all nine subjects and deemed a characteristic trait (14). Later studies have found gynecomastia to be less common in KS, representing about a third of studied adult individuals (29;90-92), although prominent or persisting pubertal gynecomastia remains an important sign of underlying KS. In a study of 25 boys with pubertal gynecomastia, three cases of KS were identified, all having prominent (Tanner \geq B3) pubertal gynecomastia at a mean age of 13.8 years (93). Even earlier onset of gynecomastia in KS has also been observed (94). One recent study reported gynecomastia in 5 of 27 (18.5 %) pubertal boys with KS, while none of 16 prepubertal non-KS boys presented with gynecomastia (86). In a Danish study, 16 out of 34 (47 %) of KS adolescents (age < 15.0 years) presented with gynecomastia (90), corresponding well with an American study finding gynecomastia in 8 of 18 (44%) of KS boys under the age of 10 (53). Although the percentages vary between studies, it is clear that persistent gynecomastia during and even before pubertal transition is a clinical sign that should lead to suspicion of KS. It may also be that gynecomastia go undetected, since many clinicians are relatively inexperienced in examining the breast area for gynecomastia.

Harry F. Klinefelter originally found the nine index cases to be of both asthenic and normal build as well as obese (14), and in our experience, men with KS do in fact come in all sizes. Indeed, newer studies do collectively give evidence to KS as generally having an increased fat mass compared with controls. In a cohort of 73 KS males, we found increased weight, hip and waist circumference, increased total and abdominal fat mass, and increased total fat percentage compared with aged matched controls (29). Other studies have also found increased weight, waist circumference (78;87), and total fat percentage (78) in KS compared with controls. Studies of the KS phenotype typically find average BMI to be above the normal range in both adults (29) and boys (53), reflecting a tendency towards overweight. However, a recent Korean study found 57 % of adult KS to be within the normal BMI range (95). Average BMI in KS is likely to have been increasing over the years, as it has in the general population. Furthermore, it is worth noticing that BMI as an indicator of fat mass should be used carefully in KS, as the increased height and lower lean body mass hampers the usability of this parameter. This is demonstrated by KS having an increased truncal fat percentage, evaluated by dual-energy x-ray absorptiometry, for any given BMI (Figure 5) (29;78). Testosterone treatment only partly compensates for this unbalance, since even after replacement therapy, total fat mass, abdominal fat mass and total body fat percentage is still increased in KS compared with controls with comparable BMI (29;78;96). Also, one study found no change in BMI or weight after 48 weeks of testosterone undecanoate in 19 men with KS (97). On the other hand, data has also been presented showing no significant difference in total body fat percentage between 48 testosterone treated KS men and an equal number of healthy controls with comparable BMI (98).

The unfavorable skewness of fat mass and lean mass is present already in KS boys who also typically present with a BMI within the normal reference range (90;96), but with

underlying increased body fat and decreased lean body mass (96). Also, one study found higher frequency of BMI above the 85th percentile and waist circumference above the 90th percentile in pubertal compared with prepubertal KS boys (86). This finding, however, did not reach statistical significance, likely due to lack of power. Controversially, another study of 89 KS boys aged 7.5 ± 2.4 did not find differences in body fat percentage or waist circumference compared with age matched controls (89). Irrespectively, a recently published randomized, double-blind and placebo controlled study of boys with KS found lower body fat percentage in boys treated with oxandrolone (n=46) versus placebo (n=47) (99). The boys in the placebo group was on average older and had higher body fat percentage at baseline, but the effects of treatment remained after statistically adjusting for these parameters. Both groups, however, reduced body fat percentage over the 2-year follow-up period.

Studies have reported other physical traits occurring more frequently in KS boys, including hypertelorism (69%), clinodactyly (74%), a high arched palate (37%), and elbow dysplasia (36%) (53;86). As with gynecomastia, attendance to these subtle signs could perhaps improve the rate of an early KS diagnosis.

It is practically impossible to identify men with KS by simple visual observation as the phenotype is often indistinguishable from men with normal karyotype, and for this reason scrotal palpation should be more routinely carried out as a simple screening tool. Further, testosterone treatment introduced late in life seems to have little effect on body composition as a whole. The effect of testosterone treatment early in life on the adult phenotype has yet to be thoroughly examined.

4.3.1 *Metabolic disturbances*

Metabolism is classically seen as a balance between catabolism and anabolism. The relative hypogonadism in KS causes imbalance with a decreased anabolic potential hindering muscle build-up and metabolic turnover of sugar and fat (100). This hypo-anabolic state impels a vicious cycle of abdominal fat deposition and global insulin resistance in the end causing increased morbidity and mortality (101), although short-term experimental hypogonadism does not induce insulin resistance (102), while a little longer term (2 weeks) withdrawal of testosterone treatment in treated hypogonadal males does induce insulin resistance (103), the issue of causality between hypogonadism and insulin resistance remain controversial. A central aspect of this vicious cycle is believed to be the development of insulin resistant Leydig cells further compromising the already hampered testosterone production in KS (104). In vitro studies show a stimulatory effect of insulin on LH-induced testosterone production in both rat and mouse Leydig cells (105), and young insulin resistant males produce less testosterone when stimulated with human choriogonadotropin (hCG) compared with non-obese men (106), indicating that insulin resistance also acts at the level of the Leydig cell.

However, the issue of what comes first, hypogonadism or obesity, has yet to be resolved. As described above, it seems the propensity for obesity in KS is present early on, before hypogonadism is properly stratifiable. Thus, researchers have some way to go before the natural history of this viscous cycle in KS is properly understood.

4.3.2 *Motor control, muscle and strength*

KS males often suffer from non-specific motor impairments such as reduced muscle strength, running speed, agility and coordination (51;107) and a large prevalence of essential tremor (108). The underlying cause for these changes is unknown.

Reduced muscle build up has been demonstrated by the finding of decreased lean body mass and intermuscular adipose tissue-free skeletal muscle mass in untreated KS compared with controls (78;109). In the same study, muscle strength (right biceps and right quadriceps) was reduced to approximately 80 % and maximum oxygen consumption to 70 % in 70 men

with KS compared with 70 age-matched controls. Likewise, exercise capacity, expressed by workload capability, and oxygen consumption were significantly impaired when comparing 48 testosterone treated KS with age and BMI matched controls (98).

The lack of muscle build up seems to be evident already during childhood, as one study found mild hypotonia in 62 % and severe hypotonia in 15 % of KS boys (53). A decreased muscle mass at the lower leg was especially noted. The findings, however, were not correlated to testosterone, perhaps lending to the theory of impaired cerebral motor function as an etiological factor for decreased muscle tone in KS boys (51;110). Also, in a very recent randomized, placebo-controlled study, no effect was seen on strength after 2 years of low-dose oxandrolone treatment in 43 KS boys ages 6.9 ± 2.2 years (111).

No study has to our knowledge looked at muscle build up in KS men vs. controls following a standardized training regime, although we would expect it to be significantly impaired in KS males. In addition, it would be interesting to investigate the potential for testosterone treatment to bettering exercise capacity in KS.

4.3.3 *Glucose and insulin*

Plasma fasting glucose has been found to be increased in adult KS, with more KS than controls having fasting glucose in the pre-diabetic or diabetic range (78;112). In boys with KS (4-13 years) however, fasting glucose appears not to be impaired (89). The changes in glucose levels are followed by higher serum insulin and HOMA-IR, a measure of insulin resistance, in KS compared with controls (78;87;98;112-114). Hyperinsulinemia and insulin resistance in KS have also been demonstrated using a hyperinsulinemic euglycemic clamp (115). In this study of five men with KS, testosterone level was found to independently predict insulin dependent glucose disposal (115). Testosterone treatment seems to only slightly improve fasting glucose values in KS (78;112;116).

In one study HOMA-IR was insignificantly higher among testosterone treated KS compared with untreated KS (78). In another study, both mean serum insulin and HOMA were numerically higher in treated versus untreated KS (no statistics applied) (98), and in yet another study, KS on testosterone treatment had lower HOMA-IR than the untreated group (87), indicating some effect of treatment. Similarly, HOMA-IR, but not serum insulin, was reduced in a group of 56 men with KS after 18 months of testosterone treatment (114). Thus, the data on the effect of testosterone treatment on features of carbohydrate metabolism in KS are somewhat conflicting. Also, although some studies have demonstrated an effect of testosterone treatment on insulin sensitivity in healthy and in obese men, it is likely that the effects in KS are indirect via a long-term reduction of visceral fat mass (117) (see 4.2 Weight and body composition).

There are indications of a considerable genetic component, as one study found that increased insulin resistance (higher HOMA1-IR) in KS was related to gene dosage of the *CSF2RA* gene located on both the X- and Y chromosome. Interestingly, higher HOMA1-IR was seen when the supernumerary X-chromosome was of paternal vs. maternal origin (87). Further, a study in KS boys demonstrated insulin resistance ($\text{HOMA} \geq 2.5$) in 24 % of KS boys down to an age of 5 years (89). This lends to a significant genetic contribution rather than impairments of carbohydrate metabolism, solely due to a vicious cycle of hypogonadism, induced fat deposition and sarcopenia. However, in the same study, HOMA was found to be increasing with age as the relative hypogonadism becomes more prominent (89).

Higher leptin has been demonstrated in KS compared with controls, with no effect on leptin levels after three months of treatment with intramuscular injections of an androgen compound (118). However, cross-sectional data show a tendency towards lower leptin after testosterone treatment when comparing untreated KS with long-term testosterone treated KS (78), without normalization of leptin levels even after long-term testosterone. In addition,

ghrelin was seen to be normalized in seven hypogonadal men, whereof four had KS after six months testosterone treatment (119). A possible mechanism for insulin resistance in KS has been proposed in a study finding overproduction of CCL2, a small chemokine expressed at sites of inflammation and associated with insulin resistance, in KS compared with controls (120).

Conclusively, larger long-term prospective randomized controlled studies are needed to clarify the effects of testosterone treatment on glucose metabolism and insulin resistance in KS, taking into account genetic aspects, changes in body composition and measurement of associated hormones, including appetite-regulating hormones such as leptin.

4.3.4 Metabolic syndrome

Although data on individual metabolic parameters in KS might be mixed, there is no doubt that, ultimately, men with KS are highly susceptible for developing metabolic disorders, namely the metabolic syndrome and type 2 diabetes. Increased prevalence of the metabolic syndrome has been demonstrated in numerous studies. In a study by Bojesen et al., 44 % of KS were classified as having metabolic syndrome according to the criteria given by the National Cholesterol Education Program/Adult Treatment Panel III (78), reflecting a five-fold increased risk. This finding was corroborated in later studies using the same criteria (98;121), the International Diabetes Federation 2004 criteria (116), or the 2009 harmonized criteria (87). Especially truncal obesity seems to predict development of the metabolic syndrome in KS (78). In KS boys, one study found the metabolic syndrome to affect 8 %, with further as much as 36 % only missing to fulfill one criteria for the diagnosis. The youngest boy who met the criteria was four years old (89).

No study has aimed specifically at evaluating the effects of testosterone treatment on preventing development of the metabolic syndrome. Still, available data are not promising. Three studies have found statistically non-significant but numerically higher rates of metabolic syndrome in treated versus untreated men with KS (87;98;116). For instance, one study found the prevalence of the metabolic syndrome to go up from 30.8 % to 38.5 % after a median duration of 4 years of testosterone treatment (116). It is of course impossible to say if the increase would have been even greater if testosterone treatment had not been initiated, and the vicious metabolic cycle had perhaps prevailed. Longitudinal studies are needed to clarify these associations.

It is as well still unclear which etiological factors are most important in causing the metabolic syndrome associated with KS. One study has demonstrated higher prevalence of the metabolic syndrome with higher expression of the differentially expressed gene *CD99* associated with gender-dependent induction of inflammatory conditions (87). Interestingly, in those KS with the highest expression of *CD99*, testosterone treatment in itself was a predictor of an increased likelihood for the presence of the metabolic syndrome. However, actual blood testosterone levels were not associated with the prevalence of the metabolic syndrome (87). Furthermore, in the study by Bojesen et al., the association between hypogonadism and features of the metabolic syndrome disappeared after controlling for truncal fat percentage (78). On the other hand, another study found measures of the metabolic syndrome in KS to be correlated with levels of insulin-like factor 3, a small peptide hormone secreted only in Leydig cells and as such a biomarker of Leydig cell function and thus indirectly testosterone production (122). Conclusively, the incidence of the metabolic syndrome in KS seems higher than in other populations of hypogonadal men (123) further lending toward a syndrome specific (genetic) background.

4.3.5 Diabetes

Consistent with other findings regarding metabolic syndrome, the prevalence of type 2 diabetes is found to be increased in KS, and studies reporting on increased prevalence of the

metabolic syndrome also find higher prevalence of type 2 diabetes (78;121). Epidemiological studies of both morbidity and mortality have found occurrence of diabetes in KS to be more than 3-fold increased (4;9). A clinical study of 39 men with KS, found the prevalence of diabetes to be 12.5 % (116), with an early average age at diagnosis of 27.1 years, and a higher prevalence than in a control group of men with idiopathic hypogonadotropic hypogonadism. Testosterone treatment did not seem to better glucose levels. The authors thus speculate that testosterone deficiency alone cannot explain the marked increase of type 2 diabetes in KS, and it even lends to a possible effect of X-chromosome dosage as even higher prevalence of diabetes has been recorded among patients with more X-chromosomes (116).

Interestingly, occurrence of type 1 diabetes also seems to be increased (9). This latter finding is supported by the recent finding of autoimmune antibodies directed against diabetes specific autoantigens in 8.2 % men with KS compared to less than 1 % of controls (124). Apart from this, very little is known about the development, treatment and prognosis of type 1 diabetes in KS.

Although the epidemiological data indicate that type 2 diabetes and the attendant comorbidity, for instance could be central to the increased mortality seen in KS, no studies have been conducted to evaluate the course of the disease or the efficacy of anti-diabetic treatments in KS. One obvious reason for this is the need for large patient cohorts to be able to include enough men with KS and concomitant diabetes.

4.3.6 Lipids

Men with KS often have dyslipidemia. In a recent German study of 132 men with KS, an unfavorable lipid profile was described with increased triglycerides and decreased HDL cholesterol compared with both male and female controls (87). Similar results are seen in the Danish cohort (78), but it could not be confirmed in an Italian study of 121 men with KS (114). However, support for an unfavorable lipid profile as an intrinsic part of KS comes also from studies in boys with KS. One study found 37% of pre-pubertal boys with KS with elevated low-density lipoprotein (LDL), and 65% with low high-density lipoprotein (HDL) (89). These findings have recently been confirmed in another study from the same group, additionally finding elevated triglycerides in 16% of 93 boys with KS ages 4-12.9 years (99). Dyslipidemia was seen in 18% of KS boys with concomitantly elevated triglycerides and low HDL in another study (77).

The only study designed to clarify the effects of testosterone treatment on lipid fractions in KS looked at treatment effects after one and four weeks, but only included ten men with KS (125), and showed an increase in total cholesterol after four weeks, while other fractions of cholesterol and triglycerides remained unaltered. Even in men with normal karyotype, the effects of testosterone treatment on lipid fractions are not clear, although some formulations, like intramuscular injections, have been associated with a reduction in HDL (126;127). Comparisons of lipid fraction between untreated and treated adult KS and controls are listed for studies covering a total of 342 untreated KS and 454 treated KS (Table 2). It can here be appreciated that substantial heterogeneity in lipid profile exists between cohorts of men with KS. However, it also seems that testosterone treatment in KS could be increasing triglyceride levels. A single study found triglycerides to decrease after testosterone treatment, but this might be caused by selection bias as the population as a whole at baseline had a mean triglycerides level at 117.6 ± 169.9 mg/dL, while the subset of patients followed before and after treatment at baseline had a mean triglyceride level of 311.5 ± 500.5 . It is thus significantly higher than the population as a whole and the normal reference range <150 mg/dL provided by the authors (114).

Testosterone treatment in KS seems to cause a decrease in HDL in observational studies (Table 2), which precludes conclusions concerning causality. It might be that alterations are only seen after long-term treatment, and thus not observed in studies with only few years

follow-up. However, a recent randomized, double-blind and placebo-controlled trial in prepubertal KS boys found lower HDL cholesterol after two years in the treated versus the placebo group ($p < 0.001$) (99).

Interestingly, lipid fractions in KS do not seem to be directly correlated to testosterone levels (121) nor to certain genetic aspects including paternal origin of the supernumerary X-chromosome, skewed X-chromosome inactivation, or number of androgen receptor CAG repeats (29). Hence the mechanism causing the dyslipidemia in KS is still largely unknown.

Taken together, KS males present with an unfavorable lipid profile, similar to what is seen in type 2 diabetes, with high total cholesterol especially due to an elevated LDL fraction with a decreased HDL fraction and also increased triglycerides. Most of the evidence concerning the effect of testosterone treatment is from observational studies and thus of low quality. There is a definite need for large, long-term and randomized studies to clarify the effect of testosterone on lipids and other metabolic parameters in KS.

Data from animal studies

There are no data from animal studies to support the specific metabolic profile of humans with KS. Mouse models would be valuable in further studying the metabolic changes seen in especially adult KS.

Summary of best evidence

The risk of type 2 diabetes is elevated 4-6 fold, the metabolic syndrome, including overweight and frank obesity, is frequently seen, and the lipid profile of many KS is unfavourable.

Areas of controversy

It is not clear whether the unhealthy metabolic profile is intrinsic to KS and dependent on the underlying genetics or in part due to shorter or longer periods with hypogonadism or is partially explained by unfavourable socioeconomic conditions. We believe that unraveling the genomics of KS will lead to new insight and possibly identify novel pathways for the development of type 2 diabetes.

4.4 Cardiovascular disease

A substantial part of the increased mortality seen in KS is based on higher prevalence of cardio- and cerebrovascular disease (in the following these two entities will be referred to as CVD). This has been demonstrated by epidemiological studies on morbidity and mortality (Figure 2)(4;9). CVD continuously accounts for approximately 30 % of deaths in America, and the epidemiological studies have found the overall risk for CVD in KS to be increased approximately 2-fold (4;8). Thus, proper management and prevention of these diseases seem pivotal. Recently, one model for cardiovascular assessment in KS has been proposed (13), and such initiatives are needed in an effort to secure the health of men with KS.

4.4.1 The heart

The basis for cardiovascular health must be a healthy heart. In Turner syndrome (45,X), the most common female sex chromosome anomaly, congenital cardiac anomalies are central to the pathology (128). Several cases of cardiac anomalies have also been reported in KS (129-133). Swerdlow et al. found mortality due to congenital cardiovascular anomalies to be more frequent in KS (standardized mortality rate: 7.3; 95 % CI: 2.4-17.1) compared with expected rates in the British population (4). In addition, malformations of the heart were found to be more frequent in KS in a study by Bojesen et al. (9). We speculate, however, that the higher rates of congenital malformations found in KS may be due to selection bias, as newborns exhibiting heart deficits are more likely to undergo chromosomal examination. Along the same lines, two studies by Fricke et al. found mitral valve prolapse to be more frequent in KS (134;135). These findings, however, have not been replicated in more recent studies with a larger sample (98;136). Impairment of ventricular diastolic function and chronotropic

incompetence in KS, on the other hand, have been reported in two large echocardiographic studies (98;136). The association between these findings and features of androgenecity, including testosterone treatment and the metabolic syndrome, remains to be elucidated. Pasquali et al. consistently described chronotropic incompetence in KS irrespective of treatment status (98), while Andersen et al. found a reduction in androgenecity to be as well associated with reduction in heart function and further accentuated in KS individuals with the metabolic syndrome (136).

Shortening of the QTc interval in KS compared with both male and female controls has also been reported by two independent recent studies (87;137). Short QTc interval is associated with an increased risk of cardiac arrhythmias and cardiac arrest. In the study by Jørgensen et al. (137), a marked effect of testosterone treatment was seen in treated men with KS having shorter QTc than in untreated men with KS, reflecting the notion of the inverse correlation between QTc and endogenous testosterone found in other populations (138). However, in the study by Zitzmann et al., no difference in QTc interval was observed between treated and untreated men with KS, and QTc was not associated with testosterone levels (87). In this study, however, shorter QTc was seen in those with paternal origin of the supernumerary X chromosome and those expressing higher levels of genes differentially expressed between KS and controls.

As such, it is not clear to what extent the KS karyotype in itself is affecting heart function, and to what extent the observed effects are due to metabolic changes and hypo-androgenism. In addition, further prospective, preferentially randomized, studies are needed to clarify the effect of testosterone treatment on heart function in KS.

4.4.2 The vasculature

Testosterone is a highly vaso-active hormone, functioning primarily as a vasodilator with an apparent protective effect against atherogenesis (139). Accordingly, Foresta et al. demonstrated reduced luminal diameter in brachial, common carotid, common femoral artery and abdominal aorta in 92 untreated KS compared with controls (140). Still, matters were complicated by the fact that no difference was seen among KS when stratifying in two groups with normal or subnormal testosterone levels respectively (140). The authors thus speculate that X chromosome gene dosage could be involved in the pathology, since the opposite, dilation of major arteries is seen in 45,X Turner syndrome (128). Whether testosterone treatment is capable of increasing arterial diameter in KS has not been investigated.

Moreover, one study has found a reduced number of endothelial progenitor cells in KS compared with controls (141). These cells play a role in repairing and regenerating the endothelial vessel lining, and a reduction in cell count could thus reflect impairment of the endothelial vessel wall. The anti-atherogenetic effect of testosterone is believed to be exerted through anti-inflammatory mechanisms. This is supported by studies in males finding an inverse relationship between serum testosterone levels and levels of pro-inflammatory cytokines in patients with coronary artery disease, type 2 diabetes and/or hypogonadism (139). The causal relationship between testosterone and atherosclerosis is, however, still unclear. Recent data from a randomized and placebo controlled multicenter study (*The Testosterone Trials*) was published, finding testosterone treatment in elderly hypogonadal men to be associated with a greater increase in coronary artery noncalcified plaque volume (142), to some extent obscuring the image of testosterone as being protective against atherosclerosis. Presence of atherosclerosis has not been systematically studied in KS. However, in the study by Foresta et al, no difference was seen in carotid intima-media thickness (cIMT) between untreated KS men and controls (140). Further, no difference was seen when stratifying for testosterone level. cIMT is a marker of atherosclerotic disease and, interestingly, another study from the same group published the same year found cIMT to be increased in 48 testosterone treated KS males compared with controls (98). It is noted,

however, that the controls in the latter study had much lower cIMT values than those in the first study, and that cIMT in the latter study further did not differ between treated and untreated KS (98;140).

Based on the morbidity pattern seen in KS, with especially a high incidence of metabolic disorders, it would seem likely that atherosclerosis and risk factors hereof, including hypertension, should also be frequent in KS. Still, as perhaps partially demonstrated by the lack of clear evidence for susceptibility to atherosclerosis, blood pressure is seemingly not increased in KS when compared with controls. Mean blood pressure is typically within the normal range (121;143) and does not differ significantly from that of matched control populations (78;98;114;140;141;144). In addition, in boys with KS, hypertension is not found in spite of other features of the metabolic syndrome being more or less frequent (89;99). In a Korean study, however, hypertension was reported in 15.2 % of 376 men with KS and in the group with BMI above 25, hypertension was found in 18.8 %. This is somewhat surprising as the worldwide prevalence of hypertension according to the WHO is approximately 40 %. Previous epidemiological studies have not looked at prevalence of hypertension, but it would be very interesting to get a more precise estimate of this from a large cohort of men with KS on and off testosterone treatment.

The finding of normal levels of adiponectin (78;98) is in further support of normal blood pressure in KS. Low levels of adiponectin are associated with hypertension and metabolic disorders. In addition, adiponectin, produced in fat cells exclusively, is negatively associated with testosterone and as such suppressed by testosterone treatment (104). Subsequently, one study found comparable but slightly increased adiponectin levels in untreated KS versus slightly suppressed levels in treated KS (112). It thus seems that the relative hypogonadism in KS could perhaps be protective against hypertension through outbalancing the reduction in adiponectin levels seen with metabolic disorders.

4.4.3 Venous thrombosis

Not surprisingly, the incidence of venous thrombosis (VTE) is increased in KS. An increased frequency of venous leg ulcers, deep vein thrombosis (DVT) and pulmonary embolism (PE) in KS was first described by Campbell and Price (145;146). Later, epidemiological studies of mortality and morbidity confirmed that the risk for VTE in KS is raised 4 to 8-fold (4;9). Recently, this was corroborated by a Swedish epidemiological study finding an adjusted standardized incidence ratio (SIR) of 6.43 (5.15-7.93) for VTE in a cohort of 1085 men with KS comparing the observed events with the expected number of events based on the national prevalence among Swedish males (7). Interestingly, the authors found an especially high relative risk for VTE in age groups <30 and 30-49 years of age (SIR 12.10 (6.22-21.21) and 11.00 (7.86-14.99), respectively). Further, the cumulative incidence of VTE in KS at age 70 was 20.8 %.

The 30-day and 1-year mortality rates after VTE are around 10 % and 20 %, respectively (147), and the collective evidence indicates that VTE in KS is significantly increasing the risk of death already at a young age. Furthermore, the Swedish study did not find any difference in VTE incidence before or after diagnosis of KS (7). This is an important finding opposing the simple explanation that the increased incidence of VTE in KS should be due to elevated hematocrit as a consequence of poorly managed testosterone treatment (148). Taking into account the KS phenotype with its specific morbidity pattern and hormonal profile, it seems fair to assume that a distortion of the hemostatic balance should be in effect. The prevailing hypothesis evolves around obesity and metabolic challenges in KS, leading to decreased fibrinolytic capacity caused by increased levels of plasminogen activator inhibitor-1 (PAI-1)(149). High BMI and low testosterone levels are associated with increased levels of PAI-1 (150;151), and two studies have indeed found higher levels of PAI-1 in KS with leg ulcerations compared with KS without leg ulcerations (152), and in KS compared with both

male and female controls (87). Yet, it is still unclear whether these observations are simply associated with fat mass or some intrinsic effects of the KS karyotype. Interestingly, in the study by Zitzmann et al., the levels of PAI-1 in testosterone treated and untreated KS were comparable (87), indicating that testosterone treatment perhaps is not capable of restoring fibrinolytic capacity. It is also possible that an effect of the altered hormonal composition in KS with a relatively elevated estrogen could potentially alter the hemostatic balance. In this context, it is also interesting to consider aromatization of exogenous testosterone compounds. Further, higher levels Factor VIII or Factor IX could be hypothesized, since the genes for these coagulation factors sit on the X-chromosome. Although increased levels of Factor VIII were described in a recent case series of VTE in six men with KS (153), the authors conclude that the frequency of thrombophilia markers in the six KS cases did not differ from a control population with VTE. Thus, larger studies evaluating the hemostatic balance in KS are needed. To this end, we are currently conducting one such study aiming at evaluating aspects of coagulation and fibrinolysis in a larger cohort of men with KS, before and after treatment with testosterone (ClinicalTrials.gov ID NCT02526628).

In clinical practice, we consult with specialists in hemostasis and coagulation and normally continue testosterone therapy among men with KS and VTE, with appropriate addition of anticoagulation therapy, and as such the clinical handling does not differ from clinical guidelines within the area.

4.4.4 Arterial thrombosis

Diabetes, obesity, unfavorable lipid profiles and an increased prevalence of autoimmune conditions are all characteristics of KS, as well as risk factors for cerebral stroke and myocardial infarction. The evidence for an increased incidence of arterial thrombosis in KS is, however, less convincing than what is the case for VTE. This is, on the other hand, in line with the lack of convincing evidence for other arterial thrombosis risk factors, atherosclerosis and hypertension, being more prevalent in KS.

Price et al. found mortality from diseases of the circulatory system to be increased in KS (154). This was mainly attributed to an increased mortality from cerebrovascular disease while the incidence of ischemic heart disease was insignificantly increased. Swerdlow et al. found mortality from cerebrovascular disease to be increased in KS (standardized mortality rate (SMR) (95 % CI); 2.2 (1.6-3.0)), while mortality from cardiovascular disease was slightly decreased (SMR (95 % CI); 0.7 (0.5-0.9)) (4). Bojesen et al., on the other hand found a higher incidence of ischemic heart disease in KS (hazard ratio (HR)(95 % CI); 1.71 (1.28-2.29)), but only an insignificant increase in incidence of cerebrovascular disease (HR (95% CI); 1.19 (0.78-1.81)) (9).

Men with KS present with a high incidence of several factors increasing the risk for atrial fibrillation, which would support a higher incidence of stroke. However, no studies have properly investigated the incidence of atrial fibrillation in KS.

In addition, when considering the incidence of arterial thrombosis in KS, it is important to consider measures of primary prevention. It is likely that men with KS are in fact, as a consequence of the morbidity pattern, more frequently offered preventive measures against arterial thrombosis, e.g. acetylsalicylic acid or statins.

Furthermore, Di Minno et al. recently demonstrated increased platelet aggregation in testosterone-treated men with KS compared with controls (144). We, on the other hand, have in an ongoing study found no evidence for increased platelet aggregation in a group of untreated men with KS (155). Further, treatment with supraphysiological doses of testosterone has been found to increase total homocysteine levels – which are also associated with an increased cardiovascular risk – in a group of 32 men with KS (156). Thus, in regard to the ongoing debate about safety of testosterone treatment, more knowledge is needed on how testosterone treatment affects cardiovascular disease risk in KS.

Data from animal studies

As for metabolic diseases, there is no evidence from animal studies, but also in this case it can be expected that such data would be of value in order to enhance our understanding of heart and vessels in KS.

Summary of best evidence

The risk of DVT and pulmonary embolism is clearly elevated in KS.

Areas of controversy

Whether the risk of heart and cerebrovascular disease is clearly elevated in KS is not clear, and further large epidemiological studies would likely elucidate this area. There is also a need for further studies of the coagulation system in KS and the effects hereon of TRT.

4.5 Bone metabolism

Because KS males all eventually develop relative or manifest hypogonadism – and relatively low testosterone and estradiol levels – it is to be expected that bone metabolism will be affected. Not surprisingly, fractures and osteoporosis occur more frequent among KS (4;8;9). Many clinical studies have looked at bone mineral density as a proxy and generally found this to be decreased (109;157), although no clear relation between serum testosterone and BMD has been found. We also found both serum markers of bone formation and bone resorption comparable to controls (109). We and others have also described decreased 25-hydroxy-vitamin D and muscle strength (109;158), and in addition to this, we have demonstrated low insulin-like factor 3 (INSL3), a new marker of Leydig cell function, in both treated and untreated KS, which was correlated with osteocalcin, a marker of bone formation, although no direct correlation was seen between INSL3 and BMD (122).

Using high resolution pQCT, we recently demonstrated distinct differences between KS and controls and showed that KS males had low volumetric BMD and especially reduced trabecular density at the tibia. Furthermore, we described the findings as being similar to what is seen in postmenopausal women, where a compromised trabecular network with low trabecular number is seen. The findings resulted in lower bone strength at the level of the tibia (159). To date, there are no randomized clinical trials investigating the effect of appropriate bone-healthy treatment with testosterone, 25-hydroxy-vitamin D and calcium supplementation among KS, but given the available data from other conditions and from observational studies (158;160;161), it seems prudent to assume that such treatments will help in keeping fractures and osteoporosis at bay.

Data from animal studies

The adult 41,XXY mouse show changes in bone morphometry with reductions in bone volume and thinner trabeculae, which resemble changes in human KS (162).

Summary of best evidence

Osteoporosis is more frequent in KS and the likely result of hypogonadism and thus relatively low levels of estradiol.

Areas of controversy

It remains to be seen if appropriate TRT will normalize the microarchitectural unfavourable changes of the bone observed in KS.

4.6 Autoimmunity

The prevalence of autoimmune disease is also increased in KS in the presence of surplus X chromosome material (163), just as it is in Turner syndrome, with a lack of X chromosomal material (164). This increase in autoimmune disease is likely due to extra X chromosomal material in KS, although no genes or genetic mechanisms have been identified. Similarly, in Turner syndrome, lack of X chromosomal material is thought to be the basis for the increased predilection for autoimmune disease (164). In a large UK registry study, Addison's disease,

type 1 diabetes, multiple sclerosis, hypothyroidism, rheumatoid arthritis, Sjögren's syndrome and systemic lupus erythematosus were all identified more frequently among KS males compared with the male background population (163), with similar findings in a Danish registry study (9). Others have also noted a much higher frequency of systemic lupus erythematosus (165;166), and a recent clinical study found a higher frequency of antibodies related to type 1 diabetes (124). Future studies should aim at dissecting the pathogenesis behind autoimmune disease and KS.

5 Fertility and sexual function

5.1 Fertility

Men with KS usually have small testicles and azoospermia (28) and account for about 10% of azoospermia cases (167). In literature, a few cases have been described where pregnancy was achieved during natural conception (168) or after IntraCyttoplasmic Sperm Injection (ICSI) using ejaculated sperm (28;169). The couple described by Crüger et al. (169) actually had another child by ICSI a couple of years later. At each treatment, about six sperm cells were found in the ejaculate. KS men with sperm in the ejaculates may be suspected to have chromosomal mosaicism in the testicles or in general. In this first case describing paternity by natural conception in KS, there is no mentioning of how many peripheral leukocytes the diagnosis was based. Furthermore, the man with KS reported in this study, had testicular volumes of 10 mL, which is unusually large for a KS man (168). Therefore, it cannot be excluded that this man might have a KS mosaicism within the blood and/or inside the testis. In other studies, however, testicular sperm has indeed been detected in KS men who probably did not have mosaicism in peripheral blood (169;170).

To date, it is not clear what actually happens in the KS testis – do 24,XY spermatogonia have the ability to complete meiosis, or do the normal spermatozoa found in some adults with KS, arise from patches of normal 23,X/23,Y spermatogonia? This latter possibility would suggest that cryptic mosaicism is present in KS, a hypothesis which so far has not been supported by much data (171). In one study of KS males with ongoing spermatogenesis, it was found that viable germ cells were euploid, but were surrounded by apparently normal functioning 47,XXY Sertoli cells (172), and the overwhelming majority of tubuli were devoid of germ cells. Similarly, it has been demonstrated in a preliminary report that intra-testicular testosterone levels among KS are higher than among controls, with a four-fold higher number of Leydig cells per tubule and a similar number of Sertoli cells per tubule, and with a tubule thickness that was twice the size of controls (173). A recent study in mice showed that trisomy biased chromosome loss occur quite frequently in induced pluripotent stem cells in XXY and XYY mice, and that these euploid XY pluripotent stem cells can develop into male germ cell lineage and become viable sperm, leading to seemingly normal offspring (174). The authors also demonstrated that this trisomy biased chromosome loss can occur in human KS fibroblasts, and thus a similar mechanism could be present in KS males, explaining the presence of ongoing normal spermatogenesis (174).

It is not understood how the extra X chromosome in KS affects spermiogenesis. A recent transcriptome study of adult KS testis showed that many mRNA were differentially expressed in Sertoli and Leydig cells (175). It is still unclear whether these changes are merely changes that occur after the demise of normal testis architecture, with extensive fibrosis and hyalinization of the seminiferous tubules (80), that occur already in childhood (176), and perhaps already starts in utero, and accelerates during puberty. Another recent study of fetal testis found a marked reduction in MAGE-A4-pre-spermatogonia by immunohistochemistry, and by transcriptome profiling of formalin-fixed, paraffin-embedded tissue, a large number of differentially expressed transcripts was found (177). The authors focus on the X chromosome PAR transcript – *AKAP17A* – and enrichment of long noncoding

RNAs, and speculate that the differential expression of these factors may perturb early gonocyte differentiation.

Until the late 1990's, the majority of men with KS were referred to treatment with donor semen. However, in a major part of men with KS minor foci with production of small numbers of spermatozoa can be found (80;172). Since spermatozoa from KS men originate in euploid germ cells (172), ICSI with these do not increase the risk of having a child with KS or other chromosomal abnormalities compared to using sperm from other men (178). The success rate in localization of such small sperm producing foci by random testicular biopsy or TESticular Sperm Extraction (TESE) is low, and multiple biopsies may damage the testicular tissue (179).

Therefore, microdissection TESE (mTESE) where larger, opaque, normal-calibrated seminiferous tubules suggested to contain spermatozoa are selectively removed by microscissors, and the removed tissue examined for presence of sperm immediately was developed (180). mTESE was found to be superior to conventional TESE in the only randomized, controlled study performed (181). The success rates in finding testicular sperm by mTESE are 44%-66% depending on patient material, experience of the surgeon and lab technicians and pretreatment of the patient with hCG or aromatase inhibitors before operation (182;183). In selected KS cases, subcapsular orchiectomy could be considered (184). One might expect a higher chance of obtaining sperm when an entire testis is removed and systematically dissected in the lab. However, it seems necessary to improve the lab procedures before this method can be adopted. Circulating levels of FSH or inhibin B do not predict the chance of obtaining sperm in men with KS (184;185). The testosterone level has been found to decrease following mTESE (186;187) as well as subcapsular orchiectomy (184). Since the majority of KS patients will benefit from testosterone therapy anyway, we consider the operative procedures to be ethically acceptable, taking into account the great wish of many couples to have their own child.

Increased age has been suggested to decrease sperm retrieval success rate. Therefore, testicular biopsies have been performed in teenage boys with the aim to cryopreserve testicular sperm. In the first early study, it was not possible to retrieve testicular sperm among seven non-mosaic KS boys 13.3-16 years of age (188), but testicular tissue was banked in the hope to develop sperm from spermatogonia in the future (189). In another European study, sperm were isolated in one of five boys aged 15-16.5 years old (190). Conversely, in one study researchers were able to retrieve sperm in seven of ten boys 14-22 years of age (mean age: 15.5y), after the boys were given testosterone replacement and aromatase inhibitor therapy for a period of 1-5 years before surgical sperm retrieval (191). Usually, testosterone replacement will have a negative influence on sperm production by a decrease of the intratesticular testosterone level, which is up to 400-fold higher than in the periphery and seems to be higher among KS than controls (173), due to inhibition of the LH secretion by negative feed-back mechanism. This must have been possible to avoid in the above-mentioned study by giving very modest testosterone doses (191). Furthermore, use of aromatase inhibitors for a long time may decrease the level of estradiol, which is an important modulator of bone structure. In a prospective study, the sperm retrieval rate (52%) in 25 non-mosaic KS boys 15-22 years of age was similar to sperm retrieval rate (62.5%) in 16 non-mosaic KS men 23 years or more (192).

In conclusion, the success rate in testicular sperm retrieval procedures is seemingly not improved by performing the procedure during adolescence. However, further studies will show if there is a place for cryopreservation of testicular tissue from KS adolescents with the aim of inducing sperm production from spermatogonia stem cells in the future. There are important ethical considerations in offering sperm retrieval and cryo preservation during adolescence or even younger, and it is not straightforward how to deal with these questions

(193), although a Belgian study showed that parents of KS adolescents were in favour of such a possibility (194). We suggest that such procedures should for now only be performed within ethically approved protocols.

Children born of KS partners are generally healthy and without chromosomal abnormalities (171). Two exceptions are triplet pregnancies from Israel where a KS fetus was therapeutically aborted (195). However, if KS occur in 1:630 boys in the background population, a few cases with 47,XXY karyotype should be expected.

Data from animal studies

The KS mouse (41,XXY or 41,XX^{Y*}) show morphologically normal spermatogonia early in life, indicating normal proliferation and migration of primordial stem cells, but already from day 12.5, or even earlier, mitotic proliferation declined and lead to eventual loss of germ cells (83;84;196), and as adult this mouse is quite similar to the human KS male, with small testes, small seminiferous tubulus containing Sertoli cells only, hyperplasia of Leydig cells and the typical hypergonadotropic hypogonadism. Recent results in the 41,XX^{Y*} mouse show that the spermatogonial stem cell pool is reduced 5-fold already at birth, indicating that this process likely starts in utero (197), and this may be due to changes in their stem cell characteristics. Here, the authors showed decreased immunohistochemical expression of spermatogonial stem cell markers LIN28A and PGP9.5, decreased mRNA expression of a number of factors including LIN28A and regulating miRNAs, indicating a reduction of the stem cell niche already in utero (197). A summary of the results from the two different mouse models concerning the testicular function has recently been published (198).

Summary of best evidence

Transcriptome data of whole testes indicate a profound deregulation of the genetic machinery underlying normal spermatogenesis and steroidogenesis. The KS male is no longer considered infertile, since many can now benefit from mTESE.

Areas of controversy

The optimal age for mTESE has not been defined, and likewise it remains to be shown whether pretreatment with hCG or aromatase inhibitors will increase the yield of spermatozoa. Banking of spermatogonia in adolescents remain a controversial area with clear ethical problems. The seemingly inevitable demise of the KS testes has not been elucidated and research within this area will be exciting in the years to come. We need genomic studies of individual cell types (eg Leydig, Sertoli, spermatogonia, etc) in order to tease out the exact temporal events underlying what has been coined “the testicular catastrophe” in KS.

5.4 Sexual function

There is a growing literature outlining an association between KS and sexual dysfunction. Among males referred to outpatient clinics due to sexual problems, an increased prevalence of KS of 1.7 % was reported (199), indicating that sexual dysfunction may be more common in KS compared to males from the background population. However, the existing studies do not reveal a clear picture. The self-reported degree of erectile dysfunction ranged from 2.5% - 23%, which was not significantly different from control men with infertility or sexual dysfunction (200-202). In contrast to this, in the largest sample to date, KS patients reported significantly decreased erectile dysfunction when compared to males from the male background population (203). These findings could reflect sampling bias. Men seeking medical consultation due to infertility or sexual dysfunction may share the same prevalence of risk factors related to erectile dysfunction as men with KS. Comorbidity such as dyslipidemia, diabetes, hypertension, metabolic syndrome and obesity are seen with a higher prevalence in men with erectile dysfunction (204) and in infertile men (205). Thus, the profile of comorbidity seen in men with KS correlates well with that seen in men with

erectile dysfunction or infertility, and it correlates well with the reported increased prevalence of erectile dysfunction in KS when compared to the male background population.

Psychological factors such as depression, which is known to decrease erectile function as well as sexual desire (206), may also have an impact on the erectile dysfunction seen in KS.

Androgen deficiency can also be related to sexual dysfunction. Testosterone therapy has been reported to have an impact on sexual motivation and mood in men with KS (207) and hypogonadal men (208;209). However, Yoshida et al. did not find any significant difference in the incidence of sexual dysfunction including sexual desire between KS men with normal total testosterone level and KS men with decreased total testosterone level ($p = 0.58$) (200). In support of this, Corona et al. also did not find any significant difference in sexual dysfunction and sexual desire between KS and controls when adjusted for total testosterone (199).

When including all the existing studies, decreased sexual desire was reported by 10-61 % of men with KS (199-201), with one study finding sexual desire to be significantly lower compared with controls (201), whereas others did not find any statistical difference between KS and controls (199;200).

Regarding premature and delayed ejaculation, perceived premature ejaculation was experienced by 9 - 65 % of men with KS (199-201), however equal to or even significantly lower than in controls. Delayed ejaculation was experienced by 7-43 % of KS men (199-201). As with erectile dysfunction, studies including subjects with sexual dysfunction or infertility found this prevalence to be non-significant (199-201). Conversely, when comparing KS with the male background population, delayed ejaculation was experienced significantly more often in men with KS (203). Data regarding orgasmic function is also divergent, with one study finding that orgasmic function was reduced in 20% of KS (200), however, not significant when compared to infertile controls. A study by Skakkebaek et al., on the other hand, found orgasmic function to be significantly decreased in KS men compared to male controls (203). Finally, testicular pain seems to be significantly more prevalent in men with KS with a prevalence of 23% (203).

With respect to frequency of intercourse, no difference was seen between KS and controls (199;200;207;210), illustrating that despite some degree of sexual dysfunction, men with KS are as sexually active as other males, irrespective of cohabitation status. However, KS males do have a significant later sexual debut (203). We recently studied criminality among males with KS in a nationwide study and found that males with KS more frequently were convicted for sexual abuse offenses, in addition to burglary and arson offenses (211). The cause for this increased criminality, in which only a minority of KS males are involved, is likely multifactorial, with influences from executive function problems, delayed social development, auditory processing deficiencies, communication deficits, having been bullied earlier in life, social behavior and cognition problems, age-(in)appropriate sexual interactions and poor decision making skills (discussed in the neurocognitive chapter).

There are a few observations of gender dysphoria and increased rates of bisexual and homosexual identity, which may suggest an increased frequency among KS males (203;212;213), however, currently there is a gap in our knowledge concerning gender identity, gender dysphoria and KS before any definitive conclusions can be made.

Summary of best evidence

The sexual dysfunction seen in men with KS most likely is an effect of their comorbidity rather than the syndrome itself, and evidence for an effect of testosterone therapy on sexual dysfunction is sparse.

Areas of controversy

More comprehensive studies including both androgen status, data on comorbidity and sexual function are needed to elucidate the level of sexual dysfunction in men with KS and the impact of comorbidity and androgens.

6 Neurocognition, quality of life, and socio-economic aspects of Klinefelter syndrome

6.1. Neurocognition

6.1.1. Cognitive dysfunctions

KS is characterized by a number of deficits in cognitive functioning, including general cognitive abilities (i.e., intelligence), language and executive functioning.

6.1.1.1 Intelligence

KS males' overall, full-scale IQ (FSIQ) is typically lower than controls (214-217), averaging about 10 points (0.6 standard deviations) below that of the general population (37;218;219), but not so low as to constitute intellectual disability. This downward shift in IQ among KS males predominantly reflects a deficit in verbal ability (VIQ) rather than performance IQ (PIQ), including non-verbal reasoning and spatial abilities, although the variability is large. This VIQ-PIQ discrepancy among KS males typically emerges early in childhood (220;221) and sometimes dissipate in adulthood (222-224). This may reflect (delayed) development of more complex skills through learning and experience. Verbal deficits that persist into adulthood (e.g., verbal memory and processing speed, lexical retrieval efficiency) may not be captured by earlier tests identifying more basic verbal dysfunction (e.g., vocabulary) at younger ages. Finally, development of PIQ may be halted as a function of hormonal and psychological tumult during puberty and/or accelerated deterioration of non-verbal processing later in life, e.g. due to cardiovascular incidents.

6.1.1.2 Language

Verbal deficits are among the most characteristic functional features of KS, identified in 70-80% of KS males (22;225). Language is also one of the broadest constructs relevant to KS, comprised of many interdependent elements, the results for which often differ across studies. Many researchers distinguish between *receptive* and *expressive* language functions (226-228) in their discussions of KS-related deficits. Receptive language skills involve the comprehension of linguistic stimuli and are largely based on perception and recognition capacities, while expressive skills are those involved in the production of linguistic content, with an emphasis on recall and vocal motor function. Receptive language deficits associated with KS include problems with auditory processing and semantic memory (217;229), word decoding and auditory discrimination and processing (230-232). In addition, KS males exhibit deficits in many expressive language skills such as speech onset (217) and articulation (233), word retrieval and verbal fluency (222;224) and word formulation, as well as general expressive skills (231;234).

Reading, writing and literacy is also heavily affected in KS (220;234). Approximately 50-75% of both children and adults with KS demonstrate some level of dyslexia (224) compared to a 7% prevalence in the background population (235).

Typically, language deficits in KS emerge early in childhood (236) and persist into adolescence and adulthood (233). Although such KS-related language problems are consistent in the literature, they are not universal. The most prominent exception is a study that found no KS deficits relative to the general population in single-word decoding, spelling, receptive or expressive vocabulary, word retrieval or verbal fluency (51). However, this lack of KS-related deficits may also reflect, at least in part, the complexity of the tasks themselves, for spelling, simple vocabulary and single-word decoding, word retrieval and verbal fluency (i.e., timed word retrieval) are all relatively simple, declarative skills, and

there is consistent evidence that KS males' linguistic performance declines with increasing task complexity (217;229;231;233). Bender et al. (1986) found no KS-related decrements in single-word decoding (218), and Graham et al. (1988) observed no KS deficits in any receptive language measures except syntactic comprehension (231).

Understanding and treating language deficits among KS males is critical for their well-being, for language is not only the foundation for one's understanding and communication with the world, it is also essential for cognitive, emotional and social development (234;237). However, developing a comprehensive understanding of KS-related language problems poses a significant challenge, given the number and complexity of linguistic functions, many of which are related (e.g. spelling and word decoding), nested (verbal and auditory memory) and/or relevant to either one or both forms (written/oral) and domains (receptive/expressive) of language.

6.1.1.3 Executive Function

Executive function (EF) refers to cognitive control processes involved in goal-directed behaviour and problem solving, such as organization, planning, judgment and decision making, with specific functions that include focused and sustained attention, holding thoughts in working memory, inhibiting irrelevant information and processing thoughts in a fluid and flexible way. KS deficits have typically been found for attention (51;217;230), inhibition (217;238;239) and both working memory and cognitive flexibility (217;230;240), although results from the relatively few EF studies among KS males are somewhat mixed (e.g. see (51;239) for divergent results). The consistent verbal EF deficits among KS males suggest a potential linguistic cause for these performance decrements, but studies have found the diminished inhibition capacity of KS males to be independent of language skills and processing speed (238), illustrating the importance of controlling for intellectual, linguistic and other potential confounds in KS research. In the most comprehensive study to date on EF among KS males, Skakkebaek et al. (2017) used extensive regression and path analyses to control for and assess the independent effects of KS status, intelligence (IQ), personality, social skills and testosterone treatment on the executive function of 69 KS males and 69 matched controls (241). We found that the impact on EF of having KS was mediated separately by IQ and social skills, and this study stands as a model for future research to better understand the potential causes of—and treatments for—EF and other deficits suffered by those with KS (241).

Data from animal models

Both mouse models have, when tested, confirmed parts of the neurocognitive deficits seen in KS. In one study, 41,XXY mice showed delayed conditional learning in a Pavlovian approach procedure also testing memory (242), and in another study 41,XX^{Y*} mice were not able to solve a memory recognition task (196).

Summary of best evidence

Both human and animal studies show consistently executive, language and intelligence deficits among many males with KS, which interacts with and affects social skills. It is clear that there are complex interactions between these different domains of neurocognition.

Areas of controversy

It is uncertain how to treat the neurocognitive deficits in men with KS best. There is a definite need for large, well-designed intervention studies to improve neurocognitive skills in KS.

6.1.2. Brain structure and physiology

6.1.2.1. Brain structure differences

A number of studies have investigated brain structure in KS males (243-251). The emerging picture is that KS males have smaller total brain volume (TBV), total gray matter volume (GMV) and total white matter volume (WMV) compared to 46,XY males.

The ventral and central parts of the brain have been found to show a distinct pattern of large volumetric differences (243-251). The medial temporal lobes, including the hippocampi, bilaterally, have been found to be more affected, along with the insula and subcortical regions such as the striatum (Figure 6 and 7). This pattern of differences to some extent mirrors that seen between 46,XX females and 46,XY males (252). Interestingly, the reverse pattern is observed in Turner syndrome (227), in that Turner syndrome females exhibit enlargements of the same areas, where KS show decreased volume. Some of these effects may be due to epigenetic mechanisms. Support for this comes from the finding that KS males with skewed X-chromosome inactivation have significantly smaller insula volume compared to KS males without X-chromosome inactivation (52) and display a general pattern of diminished grey matter volume in exactly the same regions, which are smaller in KS than in 46,XY males (Figure 6 and 7).

6.1.2.2 *The electroencephalogram*

Early studies suggested that an increased proportion of KS display slower alphas rhythms in their EEG (253;254). This, however, has not always been replicated (255;256), and the functional relevance of such a difference is uncertain.

6.1.2.3 *The Blood Oxygen Level Dependent (BOLD) signal*

One study investigated neural effects of a simple stimulus/response paradigm in order to investigate if KS display a normal blood oxygen level dependent (BOLD) signal, used as a marker of neural activation during functional magnetic resonance imaging (fMRI) (257). Given the endocrinological and physiological differences between 46,XY males and KS, it might be expected that KS would display abnormal non-specific hemodynamic responses during fMRI. This, however, was found not to be the case. KS as a group were found to have increased BOLD responses compared to healthy 46,XY males in and around the primary auditory cortices when listening to sounds (words). They were also found to display increased signal in the hand area of the motor cortex during responses to stimuli using finger presses. This effect was observed in the absence of a response time difference. In the visual cortex, however, no differences in BOLD responses were observed for visual stimuli (coloured words). This suggests that the observed differences are not due to a system-level difference in hemodynamic responses.

The BOLD response has been found to increase with age in the normal population (258). The same was found to be the case in KS, and no differences between KS and 46,XY males were found (257).

6.1.3. *Cognitive brain function*

Very few functional neuroimaging studies have investigated the neurofunctional underpinnings of KS (227). Three main topics have been investigated, each targeting a field of cognition where KS persons display some level of deficit. The first topics are executive functioning and stimulus adaptation (257). In this study, which is also touched upon in section 6.1.2.3, participants were given colour word stimuli in either the auditory or the visual modality. The visual stimuli made up a simple Stroop paradigm, testing participants' executive function. KS participants were found not to differ from 46,XY participants, neither in terms of their response time nor in terms of their Stroop effect, nor were they found to exhibit any differential brain activity during this task compared to 46,XY males. In the same study, an adaptation contrast was added by making one of the colour words occur more often than the other. Both KS and 46,XY participants adapted their response times to the stimuli to an equal extent and displayed the same type of brain activation differences for frequent and infrequent stimuli, i.e. although KS display learning disabilities, they seem to have normal adaptation to statistical properties of their perceptual input.

The second topic investigated with fMRI is language processing and lateralization (259). This study used language processing tasks and found that KS have less language

lateralization than XY males. The effects, however, were moderate and need to be replicated in a larger sample. In addition, lateralization indices were found, as it is often done, by comparing the number of activated voxels in a given region of interest across the two hemispheres. However, if KS have greater signal in auditory cortex as found by Wallentin et al. (257), then they will tend to have more activated voxels. Activation levels may thus be just above threshold in KS in e.g. the right hemisphere while they are just below threshold in controls, resulting in a seemingly greater lateralization in the controls. We conducted an exploratory analysis of lateralization of raw regression coefficients in the temporal lobe (auditory cortex) in our study of single word processing in a larger sample of KS, and found that it did not differ from that which was observed in 46,XY males (257). We did, however, find that 46,XY males had a significantly larger response to written words in the visual word form area. This effect may be related to the larger degree of dyslexia (see section 6.1.1.2) observed in Klinefelter.

A third topic is social cognition (260;261). Elevated autistic traits have been observed in KS (262;263). One of the features of this is a decreased sensitivity to facial expressions. One study found KS to display decreased activation in amygdala and the fusiform face area compared to controls (261), while another study found a tendency for the opposite effect in amygdala (260). In contrast, the latter study found that KS relied more on prefrontal brain areas for processing of facial expressions (260). We have recently described generally poorer social skills and engagement among adult KS males, and that social skills are interlinked with executive function deficits (241). More studies are needed to see if a consistent pattern emerges.

Summary of best evidence

There are consistent changes in the size of a number of brain regions on MRI. Functional neuroimaging studies have described discrete changes in auditory and language processing, while findings regarding social cognition are equivocal, and tasks on executive functioning has been described to be similar to controls.

Areas of controversy

In KS the interconnectivity between different brain regions has not been studied. Functional studies are few and may not have been performed with appropriate design, and thus not targeted relevant neurocognitive abilities. Likewise, it is not clear if TRT affects functional neuroimaging.

6.4 Quality of life

Through the past decade, a few studies focusing on the impact of living with KS have emerged. These studies indicate that KS has important implications for the majority of these people, both as children, as adolescents and as adults. In the study by Turriff et al. including 310 adolescents and adults with KS, 76 % answered that having KS had significant negative consequence on their life (264). This is in line with the significant lower quality of life (QoL) reported in both boys and men with KS when compared to either population normative data (265), a male reference group (266), a male control group (203) or without a comparison group (86). In boys with KS, Close et al. found that 67 % of the boys reported adverse quality of life with low scores on all subscales (physical, psychosocial, emotional, social) (86). In addition, their data showed that both total QoL, physical QoL and social QoL were inversely associated with the severity of the physical phenotype, and that 22% of the variance in total QoL could be explained by the physical phenotype (86).

Similar to the pattern in boys with KS, three studies in adult men with KS reported statistically significant decrements in all eight QoL subdomains (physical functioning, social functioning, role physical, role emotional, mental health, vitality, pain, general health) of the Short Form Health Survey (SF-36) (203;266;267). In addition, one of these studies also reported statistically significant decrements in all subscales of the abbreviated version of the

WHO's QoL Assessment (physical health, psychological health, social relationships, environmental health) (203). Regarding predictors of QoL, the study by Ronde et al. demonstrated a positive and significant association between education and scores on the eight subscales of QoL, with multiple regression models finding a significant association between education and subscale vitality and general health (266).

Poorer sleep quality with more sleep disturbance, high impact of poor sleep on daily functioning and frequent use of sleep medication were seen in a Norwegian questionnaire study (267). Here, poor sleep quality was a strong predictor of poorer QoL scores (267). In the study by Skakkebaek et al., predictors of mental QoL and physical QoL were evaluated by structural equation models including both mental and physical subscales from the SF-36 and the abbreviated version of the WHO's QoL Assessment (203). In these models, lower mental QoL among men with KS were associated with lower income and living without a partner, whereas lower physical QoL were associated with less employment, lower income, daily medicine intake, and less physical activity (203). This study also found evidence that having KS is in itself associated with poorer life quality (203). In addition to the two above mentioned studies among adults with KS, a third study has evaluated subjective well-being and other psychosocial outcomes in adults with KS (265). Their data showed that higher subjective well-being and psychosocial outcomes were associated with active employment status, increased social support and a less severe phenotype (265). In another questionnaire study among adult Norwegian KS, low scores on the Short-form 36 were also prevalent (267). These findings are further supported by the study by Turriff et al., which provided further insight into the impact of living with KS using open-ended questions. The greatest challenge faced by adolescent and adults with KS were according to their survey infertility and psychological comorbidity, in addition to learning disabilities, physical phenotype, social relationships, employment problems, challenges with health care providers and testosterone treatment challenges (268).

Whether testosterone has an impact on QoL has been investigated in two of the existing studies (86;203). Close et al. did not find any association between total testosterone level in blood and quality of life for boys with KS (86), and Skakkebaek et al. found no significant difference in QoL scores between treated and non-treated adult men with KS (203). However, both these studies were cross-sectional, and longitudinal studies are needed to properly evaluate the effect of testosterone substitution on QoL. Clinically, we see a clear benefit in most KS males from TRT with increased vigor, improved social functioning, decreased sleep length and improved sexual function.

When KS males are asked about the level of satisfaction with health care services, the majority feel dissatisfied (203;267), which is disconcerting. Many are followed by general practitioners or not seen at all in the health care system. This level of detachment from health care professionals may pertain to understanding the fundamentals of what KS is among patients, expectations to the health care system not being met, lack of understanding on behalf of the health care professional of the underpinnings of KS, or a mix of these issues. We believe that it calls for improved education among health care specialists, the need for a holistic approach to the KS patient including a careful pedagogical approach in explaining how the syndrome affects individuals, and more research into the complex interactions between genotype, phenotype and testosterone substitution in KS.

Summary of best evidence

The majority of boys and men with KS suffer from poorer mental and physical quality of life, and with respect to predictors of QoL, phenotype severity/comorbidities and less social support/living without a partner among others may be associated with poorer QoL.

Areas of controversy

Only a minor degree of variance in QoL has been explained by the factors mentioned above, indicating that other factors may have an impact on QoL in boys and men with KS. The influence of TRT has only been sparingly investigated.

6.5 Socioeconomic status

Socioeconomic measures, such as education, employment and income, have long been found to impact people's general health and life expectancy across populations (269). From epidemiological studies, it is clear that educational attainment among KS males is considerably lower than the male population in general, and similar to males with 47,XYY syndrome (10;43). It is also apparent that cohabitation and becoming a father (with donor semen or TESE) is much less frequent among KS than other males (10;43), and that employment rates are also lower and in combination, these socioeconomic variables affect mortality negatively (10).

Questionnaires and clinical studies have shown that many KS are underemployed, unemployed or on disability pensions (203;265;267;270). There is undoubtedly an influence from the increased and varied morbidity affecting many KS (9) and their vocational attainment, which again forms an interplay with the ability to perform well in other areas, such as cohabitation and the chance of becoming a father. How testosterone substitution fits into this picture is not clear, however, in clinical practice, we encounter many KS males who suffer from musculoskeletal ailments, where low muscle mass, strength and tone is a likely forerunner. Therefore, we see a pressing need for longitudinal evaluation of the effect of testosterone therapy on a broad range of measures, also including measures of QoL and socioeconomy.

Summary of best evidence

The socioeconomic achievement of the average KS male is much poorer than the average male in society. It affects all aspects of socio-economic status, including educational achievement, cohabitation, fatherhood, employment and income.

Areas of controversy

It is not clear if earlier diagnosis can change the educational and thus the socioeconomic course for the average KS male and if early TRT can affect these parameters.

6.6 Hypogonadism and effects of testosterone supplementation

As stated, evidence of lower levels of testosterone, perhaps already during fetal life (29;72;80;271;272), neonatally (273;274) and at least around mid-puberty (79;275), suggests that hypogonadism as well as the hypergonadotropic hypogonadism may have an impact on behavior and neuro-cognition in KS, as sex hormones already from early fetal life are known to influence neurodevelopment and the brain (276-279). This raises the question of whether persons with KS may benefit from testosterone treatment early in life to improve their cognitive and social functions. Currently testosterone therapy is routinely administered to the majority of patients diagnosed with KS, usually starting around puberty or at the onset of hypogonadism later in life (Table 4 and 5). Whether intervention with testosterone treatment at this age or even earlier may benefit patients with KS regarding cognitive and social functions has been investigated by very few studies.

In a retrospective study, Samango-Sprouse et al. evaluated the effect of three months of early testosterone treatment (25 mg testosterone-enanthate) in infants (age between four and fifteen months) (280). They found evidence of a positive effect on cognitive domains at three and six years of age, including a positive effect on motor function at six years of age (280). At the ages of 9-11 years, a significant positive effect on social behavior was seen (281). In addition to these studies, a double, blinded, randomized study evaluating the effect of two years of low-dose oral androgen therapy (oxandrolone) in boys with KS aged 4-12 reported

improvements in visual-motor performance, social functions and aspects of anxiety and depression after 24-month of treatment, however no effect were seen on general cognitive function (111). Regarding testosterone treatment in adolescence, evidence for an impact of testosterone treatment on cognitive and social functions comes from two quite old observational studies both reporting a positive effect on learning, concentration, mood and social function (282;283), but no controlled trials exist in adolescent boys with KS. In contrast to these studies in boys and adolescent with KS, existing non-randomized, cross-sectional studies of boys and adults with KS have found no effect of testosterone treatment nor testosterone concentration on cognitive, social and motor functions (51;241;284;285), except a single study reporting a positive effect of testosterone treatment on verbal fluency (250).

Although recently published studies in boys with KS have shown encouraging results regarding the effect of testosterone treatment on cognitive and social functions, randomized controlled trials are indispensable to further elucidate the impact of testosterone therapy in both infants, boys, adolescent and adult men with KS, and to identify the most optimal treatment protocol regarding testosterone preparation, dose and age for initiating such therapy. In addition, these studies should also assess potential adverse effect of testosterone treatment.

Summary of best evidence

There is only scant evidence that TRT in infants and boys has positive effects on cognitive and social functions, and no good evidence for this in adolescence or adulthood.

Areas of controversy

Better, larger long-term studies of the effect of TRT on social and neurocognitive functions are needed in all age groups. We recommend that randomized controlled trials are indispensable to further elucidate the impact of TRT in both infants, boys, adolescent and adult men with KS, and to identify the most optimal treatment protocol regarding testosterone preparation, dose and age for initiating such therapy. In addition, these studies should also assess potential adverse effect of testosterone treatment.

7 Current state of the art

7.1 Clinical care

As mentioned throughout this review, testosterone substitution therapy remains a cornerstone of proper treatment of males with KS. Although there are many unanswered questions concerning timing, dose and route of administration, we recommend the initiation of testosterone replacement therapy once the first signs of elevated LH and FSH occur, to secure a proper masculine development of sexual characteristics during adolescence, and to enable proper peak bone mass and muscle mass to prevent osteoporosis during old age. We discuss fertility issues before commencement of therapy, and postponement of testosterone therapy can be necessary if one wants to retrieve viable sperm at this stage. In pubertal KS boys it has been reported that testosterone therapy increase energy and endurance, improves mood, concentration and relations to others (283), and there is some evidence of increased psychosocial problems in periods without testosterone treatment in pubertal KS (286). We argue for lifelong testosterone treatment in order to prevent life style diseases such as osteoporosis, obesity, metabolic syndrome and diabetes, although this practice is not evidence-based. Treatment in a large group of young hypogonadal men of mixed origin (whereof some had KS) has been shown to have a positive impact also on fat mass, muscle mass and muscle strength, as well as sexual activity and related areas, and it improves positive aspects of mood (209). In older hypogonadal males, limited data suggest positive effects of treatment on visuospatial cognition and verbal memory (287). Some KS patients

have normal testosterone values, but most have increased gonadotropin levels, an unfavorable body composition and low hematocrit, indicative of a relative hypogonadism. Others with KS may not realize that they have typical hypogonad symptoms, and a trial period of treatment may show the benefits of treatment, using bivariate charts of testosterone vs. LH for proper dosage (82). In children and adolescents dose escalation must be considered (288), starting with oral or transdermal treatment.

We aim to normalize LH and FSH during testosterone therapy and to avoid elevated hemoglobin and hematocrit, which is a common problem during treatment. Clinically, we note that about two thirds of patients in our clinic prefer longacting testosterone undecanoate or testosterone enanthate, and the remaining third of patients prefer testosterone gel, where especially brands enabling dose titration (Tostran) are popular (Table 4). As stated, we need large observational – and preferably randomized controlled studies – to answer questions related to efficacy and side effects through all phases of life. In particular, there is a scarcity of data on life with KS during middle age into senescence. Clinically, we see a mounting burden of comorbidity, which has rarely been documented in published research. We treat comorbidities according to consensus guidelines.

Concerning the many neurocognitive problems that males with KS can encounter, we are increasingly using neuropsychologists to provide neurocognitive therapy (Table 5).

Based on the published research to date, we urge for the creation of multidisciplinary clinics around the world and stress that care of KS males should take place in such units. This will ensure pervasive care from childhood through adolescence and into adulthood. We believe that centers around the world caring for KS should implement policies to this end.

8 Perspectives

Males with KS face a bewildering array of medical, neurocognitive and social problems, which are only beginning to become apparent in recent years. Clearly, there are complex interactions between genotype and phenotype, many of which we do not yet fully understand. We need to develop a more thorough understanding of the fundamental genetics and genomics of the syndrome, in order to fully address the endocrine, neurocognitive and cardiovascular disturbances. For example, is the testicular demise inevitable, or is there a possibility for rescuing testicular function, thus possibly avoiding infertility and the need for testosterone substitution? Why is it so difficult to diagnose KS? How detrimental is late diagnosis to the life of KS males? Would early diagnosis improve the lives of males with KS materially? It is clear that the current diagnostic approach is not sufficient, and we advocate for the incorporation of diagnostics of sex chromosome abnormalities, including KS, into neonatal screening programs. It is currently not clear which methodology would be most appropriate to use in a neonatal screening program, and therefore the costs of such an intervention is not yet clear.

Future research should also focus at delineating the complex interactions between the genotype and complex neurocognitive phenotype, both to understand the intricacies of the KS brain, and how the observed changes spells out clinically, but also to devise more efficient and effective treatment strategies. Thus, there is a need for much larger international collaborative efforts, in order to study genotype-phenotype relations across all ages (we envision the inclusion of >10,000 KS), large epidemiological studies with merging of multiple registries to better delineate mortality, morbidity, medicinal use and laboratory tests (level of testosterone, LH, hemoglobin, etc), but also for intervention trials to study the effects of TRT and neurocognitive treatment.

9. Funding

This work was supported by grants from the Novo Nordisk Foundation, Hede Nielsens Fond, the Lundbeck foundation, the Augustinus Foundation, Aase and Einar Danielsen Foundation and Aarhus University.

Novo Nordisk Research Foundation, Claus H. Gravholt; Lundbeckfonden (DK), Anne Skakkebaek; Augustinus Fonden (DK), Anne Skakkebaek; Aase og Ejnar Danielsens Fond (DK), Anne Skakkebaek; Familien Hede Nielsens Fond (DK), Claus H. Gravholt; Aarhus Universitet (DK), Anne Skakkebaek

*** Reprint requests and corresponding author:** Dr Claus H Gravholt, MD, PhD, Department of Endocrinology and Internal Medicine (MEA), Aarhus University Hospital, Norrebrogade 44, DK-8000 Aarhus C, Denmark. Email: ch.gravholt@dadlnet.dk

Disclosures:

The authors have nothing to disclose.

10. References

Reference List

1. **Bojesen A, Juul S, Gravholt CH** 2003 Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. *J Clin Endocrinol Metab* 88:622-626
2. **Groth KA, Skakkebaek A, Host C, Gravholt CH, Bojesen A** 2013 Klinefelter syndrome--a clinical update. *J Clin Endocrinol Metab* 98:20-30
3. **Herlihy AS, Halliday JL, Cock ML, McLachlan RI** 2011 The prevalence and diagnosis rates of Klinefelter syndrome: an Australian comparison. *Med J Aust* 194:24-28
4. **Swerdlow AJ, Higgins CD, Schoemaker MJ, Wright AF, Jacobs PA** 2005 Mortality in patients with Klinefelter syndrome in Britain: a cohort study. *J Clin Endocrinol Metab* 90:6516-6522
5. **Swerdlow AJ, Schoemaker MJ, Higgins CD, Wright AF, Jacobs PA** 2005 Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. *J Natl Cancer Inst* 97:1204-1210
6. **Ji J, Zoller B, Sundquist J, Sundquist K** 2016 Risk of solid tumors and hematological malignancy in persons with Turner and Klinefelter syndromes: A national cohort study. *Int J Cancer* 139:754-758
7. **Zoller B, Ji J, Sundquist J, Sundquist K** 2016 High Risk of Venous Thromboembolism in Klinefelter Syndrome. *J Am Heart Assoc* 5:e003567
8. **Bojesen A, Juul S, Birkebaek N, Gravholt CH** 2004 Increased mortality in Klinefelter syndrome. *J Clin Endocrinol Metab* 89:3830-3834
9. **Bojesen A, Juul S, Birkebaek NH, Gravholt CH** 2006 Morbidity in Klinefelter syndrome: a Danish register study based on hospital discharge diagnoses. *J Clin Endocrinol Metab* 91:1254-1260
10. **Bojesen A, Stochholm K, Juul S, Gravholt CH** 2011 Socioeconomic trajectories affect mortality in Klinefelter syndrome. *J Clin Endocrinol Metab* 96:2098-2104
11. **Bonomi M, Rochira V, Pasquali D, Balercia G, Jannini EA, Ferlin A** 2017 Klinefelter syndrome (KS): genetics, clinical phenotype and hypogonadism. *J Endocrinol Invest* 40:123-134
12. **Davis S, Howell S, Wilson R, Tanda T, Ross J, Zeitler P, Tartaglia N** 2016 Advances in the Interdisciplinary Care of Children with Klinefelter Syndrome. *Adv Pediatr* 63:15-46

13. **Salzano A, Arcopinto M, Marra AM, Bobbio E, Esposito D, Accardo G, Giallauria F, Bossone E, Vigorito C, Lenzi A, Pasquali D, Isidori AM, Cittadini A** 2016 Klinefelter syndrome, cardiovascular system, and thromboembolic disease: review of literature and clinical perspectives. *Eur J Endocrinol* 175:R27-R40
14. **Klinefelter HF, Reifenstein EC, Albright F** 1942 Syndrome characterized by gynecomastia, aspermatogenesis without a-leydigism, and increased excretion of follicle-stimulating hormone. *J Clin Endocrinol* 2:615-627
15. **Jacobs PA, STRONG JA** 1959 A case of human intersexuality having a possible XXY sex-determining mechanism. *Nature* 183:302-303
16. **Nielsen J, Wohler M** 1990 Sex chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus, Denmark. *Birth Defects Orig Artic Ser* 26:209-223
17. **Taylor AI, Moores EC** 1967 A sex chromatin survey of newborn children in two London hospitals. *J Med Genet* 4:258-259
18. **Ratcliffe SH** 1976 Development of children with sex chromosome abnormalities. *Proc R Soc Med* 69:189-191
19. **Hamerton JL, Canning N, Ray M, Smith S** 1975 A cytogenetic survey of 14,069 newborn infants. I. Incidence of chromosome abnormalities. *Clin Genet* 8:223-243
20. **Bochkov NP, Kuleshov NP, Chebotarev AN, Alekhin VI, Midian SA** 1974 Population cytogenetic investigation of newborns in Moscow. *Humangenetik* 22:139-152
21. **Higurashi M, Iijima K, Ishikawa N, Hoshina H, Watanabe N** 1979 Incidence of major chromosome aberrations in 12,319 newborn infants in Tokyo. *Hum Genet* 46:163-172
22. **Leonard MF, Schowalter JE, Landy G, Ruddle FH, Lubs HA** 1979 Chromosomal abnormalities in the New Haven newborn study: a prospective study of development of children with sex chromosome anomalies. *Birth Defects Orig Artic Ser* 15:115-159
23. **MACLEAN N, HARDEN DG, BROWN WM, BOND J, MANTLE DJ** 1964 Sex-chromosome abnormalities in newborn babies. *Lancet* 1:286-290
24. **Viuff MH, Stochholm K, Ulbjerg N, Nielsen BB, the Danish Fetal Medicine Study Group, Gravholt CH** 2015 Only a minority of sex chromosome abnormalities are detected by the Danish national prenatal screening program for Down syndrome. *Hum Reprod* 30:2419-2426
25. **Coffee B, Keith K, Albizua I, Malone T, Mowrey J, Sherman SL, Warren ST** 2009 Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. *Am J Hum Genet* 85:503-514
26. **Nieschlag E, Behre HM, Bouchard P, Corrales JJ, Jones TH, Stalla GK, Webb SM, Wu FC** 2004 Testosterone replacement therapy: current trends and future directions. *Hum Reprod Update* 10:409-419
27. **Tartaglia N, Ayari N, Howell S, D'Epagnier C, Zeitler P** 2011 48,XXYY, 48,XXXY and 49,XXXXY syndromes: Not just variants of Klinefelter syndrome. *Acta Paediatr* 101:2227
28. **Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E** 2004 Klinefelter's syndrome. *Lancet* 364:273-283
29. **Chang S, Skakkebaek A, Trolle C, Bojesen A, Hertz JM, Cohen A, Hougaard DM, Wallentin M, Pedersen AD, Ostergaard JR, Gravholt CH** 2015 Anthropometry in Klinefelter syndrome - multifactorial influences due to CAG length, testosterone treatment and possibly intrauterine hypogonadism. *J Clin Endocrinol Metab* 100:E508-E517

30. **Abramsky L, Chapple J** 1997 47,XXY (Klinefelter syndrome) and 47,XYY: estimated rates of and indication for postnatal diagnosis with implications for prenatal counselling. *Prenat Diagn* 17:363-368
31. **Pescia G, Guex N, Iseli C, Brennan L, Osteras M, Xenarios I, Farinelli L, Conrad B** 2017 Cell-free DNA testing of an extended range of chromosomal anomalies: clinical experience with 6,388 consecutive cases. *Genet Med* 19:169-175
32. **Jeon KC, Chen LS, Goodson P** 2012 Decision to abort after a prenatal diagnosis of sex chromosome abnormality: a systematic review of the literature. *Genet Med* 14:27-38
33. **Berglund A, Johannsen TH, Stochholm K, Viuff MH, Fedder J, Main KM, Gravholt CH** 2016 Incidence, Prevalence, Diagnostic Delay, and Clinical Presentation of Female 46,XY Disorders of Sex Development. *J Clin Endocrinol Metab* 101:4532-4540
34. **Stochholm K, Juul S, Gravholt CH** 2010 Mortality and incidence in women with 47,XXX and variants. *Am J Med Genet A* 152A:367-372
35. **Stochholm K, Juul S, Gravholt CH** 2010 Diagnosis and mortality in 47,XYY persons: a registry study. *Orphanet J Rare Dis* 5:15
36. **Berglund A, Johannsen TH, Stochholm K, Aksglaede L, Fedder J, Viuff MH, Main KM, Gravholt CH** 2017 Incidence, prevalence, diagnostic delay, morbidity, mortality and socioeconomic status in males with 46,XX disorders of sex development: a nationwide study. *Hum Reprod* 32:1751-1760
37. **Skakkebaek A, Wallentin M, Gravholt CH** 2015 Neuropsychology and socioeconomic aspects of Klinefelter syndrome: new developments. *Curr Opin Endocrinol Diabetes Obes* 22:209-216
38. **Nieschlag E, Ferlin A, Gravholt CH, Gromoll J, Kohler B, Lejeune H, Rogol AD, Wistuba J** 2016 The Klinefelter syndrome: current management and research challenges. *Andrology* 4:545-549
39. **Herlihy AS, Gillam L, Halliday JL, McLachlan RI** 2011 Postnatal screening for Klinefelter syndrome: is there a rationale? *Acta Paediatr* 101:2227
40. **Grosse SD, Rogowski WH, Ross LF, Cornel MC, Dondorp WJ, Khoury MJ** 2010 Population screening for genetic disorders in the 21st century: evidence, economics, and ethics. *Public Health Genomics* 13:106-115
41. **Perez-Cornago A, Key TJ, Allen NE, Fensom GK, Bradbury KE, Martin RM, Travis RC** 2017 Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort study. *Br J Cancer* 117:1562-1571
42. **Marmot M, Allen J, Bell R, Bloomer E, Goldblatt P** 2012 WHO European review of social determinants of health and the health divide. *Lancet* 380:1011-1029
43. **Stochholm K, Juul S, Gravholt CH** 2012 Socio-economic factors affect mortality in 47,XYY syndrome-A comparison with the background population and Klinefelter syndrome. *Am J Med Genet A* 158A:2421-2429
44. **Schoemaker MJ, Swerdlow AJ, Higgins CD, Wright AF, Jacobs PA** 2008 Mortality in women with Turner syndrome in Great Britain: a national cohort study. *J Clin Endocrinol Metab* 93:4735-4742
45. **Stochholm K, Hjerrild B, Mortensen KH, Juul S, Frydenberg M, Gravholt CH** 2012 Socio-economic parameters and mortality in Turner syndrome. *Eur J Endocrinol* 166:1013-1019
46. **Stochholm K, Juul S, Gravholt CH** 2013 Poor socio-economic status in 47,XXX --an unexpected effect of an extra X chromosome. *Eur J Med Genet* 56:286-291
47. **Bellott DW, Hughes JF, Skaletsky H, Brown LG, Pyntikova T, Cho TJ, Koutseva N, Zaghlul S, Graves T, Rock S, Kremitzki C, Fulton RS, Dugan S, Ding Y, Morton D, Khan Z, Lewis L, Buhay C, Wang Q, Watt J, Holder M, Lee S, Nazareth L,**

Rozen S, Muzny DM, Warren WC, Gibbs RA, Wilson RK, Page DC 2014 Mammalian Y chromosomes retain widely expressed dosage-sensitive regulators. *Nature* 508:494-499

48. **Belling K, Russo F, Jensen AB, Dalgaard MD, Westergaard D, Rajpert-De ME, Skakkebaek NE, Juul A, Brunak S** 2017 Klinefelter syndrome comorbidities linked to increased X chromosome gene dosage and altered protein interactome activity. *Hum Mol Genet* 10

49. **Thomas NS, Hassold TJ** 2003 Aberrant recombination and the origin of Klinefelter syndrome. *Hum Reprod Update* 9:309-317

50. **Jacobs PA, Hassold TJ, Whittington E, Butler G, Collyer S, Keston M, Lee M** 1988 Klinefelter's syndrome: an analysis of the origin of the additional sex chromosome using molecular probes. *Ann Hum Genet* 52:93-109

51. **Ross JL, Roeltgen DP, Stefanatos G, Benecke R, Zeger MP, Kushner H, Ramos P, Elder FF, Zinn AR** 2008 Cognitive and motor development during childhood in boys with Klinefelter syndrome. *Am J Med Genet A* 146A:708-719

52. **Skakkebaek A, Bojesen A, Kristensen MK, Cohen A, Hougaard DM, Hertz JM, Fedder J, Laurberg P, Wallentin M, Ostergaard JR, Pedersen AD, Gravholt CH** 2014 Neuropsychology and brain morphology in Klinefelter syndrome - the impact of genetics. *Andrology* 2:632-640

53. **Zeger MP, Zinn AR, Lahlou N, Ramos P, Kowal K, Samango-Sprouse C, Ross JL** 2008 Effect of ascertainment and genetic features on the phenotype of Klinefelter syndrome. *J Pediatr* 152:716-722

54. **Zinn AR, Ramos P, Elder FF, Kowal K, Samango-Sprouse C, Ross JL** 2005 Androgen receptor CAGn repeat length influences phenotype of 47,XXY (Klinefelter) syndrome. *J Clin Endocrinol Metab* 90:5041-5046

55. **Stemkens D, Roza T, Verrij L, Swaab H, van Werkhoven MK, Alizadeh BZ, Sinke RJ, Giltay JC** 2006 Is there an influence of X-chromosomal imprinting on the phenotype in Klinefelter syndrome? A clinical and molecular genetic study of 61 cases. *Clin Genet* 70:43-48

56. **Bruining H, van Rijn S, Swaab H, Giltay J, Kates W, Kas MJ, Engeland HV, Sonnevile LD** 2010 The parent-of-origin of the extra X chromosome may differentially affect psychopathology in Klinefelter syndrome. *Biol Psychiatry*

57. **Wikstrom AM, Painter JN, Raivio T, Aittomaki K, Dunkel L** 2006 Genetic features of the X chromosome affect pubertal development and testicular degeneration in adolescent boys with Klinefelter syndrome. *Clin Endocrinol (Oxf)* 65:92-97

58. **Lyon MF** 1961 Gene action in the X-chromosome of the mouse (*Mus musculus* L.). *Nature* 190:372-3.:372-373

59. **Tuttelmann F, Gromoll J** 2010 Novel genetic aspects of Klinefelter's syndrome. *Mol Hum Reprod* 16:386-395

60. **Bojesen A, Hertz JM, Gravholt CH** 2011 Genotype and phenotype in Klinefelter syndrome - impact of androgen receptor polymorphism and skewed X inactivation. *Int J Androl* 34:e642-e648

61. **Ross NL, Wadekar R, Lopes A, Dagnall A, Close J, DeLisi LE, Crow TJ** 2006 Methylation of two *Homo sapiens*-specific X-Y homologous genes in Klinefelter's syndrome (XXY). *Am J Med Genet B Neuropsychiatr Genet* 141B:544-548

62. **Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E** 2004 X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in klinefelter patients. *J Clin Endocrinol Metab* 89:6208-6217

63. **Chamberlain NL, Driver ED, Miesfeld RL** 1994 The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. *Nucleic Acids Res* 22:3181-3186
64. **Paduch DA, Fine RG, Bolyakov A, Kiper J** 2008 New concepts in Klinefelter syndrome. *Curr Opin Urol* 18:621-627
65. **Samplaski MK, Lo KC, Grober ED, Millar A, Dimitromanolakis A, Jarvi KA** 2014 Phenotypic differences in mosaic Klinefelter patients as compared with non-mosaic Klinefelter patients. *Fertil Steril* 101:950-955
66. **Rao E, Weiss B, Fukami M, Rump A, Niesler B, Mertz A, Muroya K, Binder G, Kirsch S, Winkelmann M, Nordsiek G, Heinrich U, Breuning MH, Ranke MB, Rosenthal A, Ogata T, Rappold GA** 1997 Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. *Nat Genet* 16:54-63
67. **Sharma A, Jamil MA, Nuesgen N, Schreiner F, Priebe L, Hoffmann P, Herns S, Nothen MM, Frohlich H, Oldenburg J, Woelfle J, El-Maarri O** 2015 DNA methylation signature in peripheral blood reveals distinct characteristics of human X chromosome numerical aberrations. *Clin Epigenetics* 7:76-0112
68. **Viana J, Pidsley R, Troakes C, Spiers H, Wong CC, Al-Sarraj S, Craig I, Schalkwyk L, Mill J** 2014 Epigenomic and transcriptomic signatures of a Klinefelter syndrome (47,XXY) karyotype in the brain. *Epigenetics* 9:587-599
69. **Trolle C, Nielsen MM, Skakkebaek A, Lamy P, Vang S, Hedegaard J, Nordentoft I, Orntoft TF, Pedersen JS, Gravholt CH** 2016 Widespread DNA hypomethylation and differential gene expression in Turner syndrome. *Sci Rep* 6:34220. doi: 10.1038/srep34220.:34220
70. **Cerase A, Pintacuda G, Tattermusch A, Avner P** 2015 Xist localization and function: new insights from multiple levels. *Genome Biol* 16:166. doi: 10.1186/s13059-015-0733-y.:166-0733
71. **Quinn JJ, Chang HY** 2015 Unique features of long non-coding RNA biogenesis and function. *Nat Rev Genet* 17:47-62
72. **Manning JT, Kilduff LP, Trivers R** 2013 Digit ratio (2D:4D) in Klinefelter's syndrome. *Andrology* 1:94-99
73. **Lutchmaya S, Baron-Cohen S, Raggatt P, Knickmeyer R, Manning JT** 2004 2nd to 4th digit ratios, fetal testosterone and estradiol. *Early Hum Dev* 77:23-28
74. **Cabrol S, Ross JL, Fennoy I, Bouvattier C, Roger M, Lahlou N** 2011 Assessment of Leydig and Sertoli Cell Functions in Infants with Nonmosaic Klinefelter Syndrome: Insulin-Like Peptide 3 Levels Are Normal and Positively Correlated with LH Levels. *J Clin Endocrinol Metab*
75. **Ratcliffe SG, Read G, Pan H, Fear C, Lindenbaum R, Crossley J** 1994 Prenatal testosterone levels in XXY and XYY males. *Horm Res* 42:106-109
76. **Aksela L, Petersen JH, Main KM, Skakkebaek NE, Juul A** 2007 High normal testosterone levels in infants with non-mosaic Klinefelter's syndrome. *Eur J Endocrinol* 157:345-350
77. **Davis S, Lahlou N, Bardsley M, Temple MC, Kowal K, Pyle L, Zeitler P, Ross J** 2016 Gonadal function is associated with cardiometabolic health in pre-pubertal boys with Klinefelter syndrome. *Andrology* 4:1169-1177
78. **Bojesen A, Kristensen K, Birkebaek NH, Fedder J, Mosekilde L, Bennett P, Laurberg P, Frystyk J, Flyvbjerg A, Christiansen JS, Gravholt CH** 2006 The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. *Diabetes Care* 29:1591-1598

79. **Salbenblatt JA, Bender BG, Puck MH, Robinson A, Faiman C, Winter JS** 1985 Pituitary-gonadal function in Klinefelter syndrome before and during puberty. *Pediatr Res* 19:82-86
80. **Aksglaede L, Wikstrom AM, Rajpert-De Meyts E, Dunkel L, Skakkebaek NE, Juul A** 2006 Natural history of seminiferous tubule degeneration in Klinefelter syndrome. *Hum Reprod Update* 12:39-48
81. **Whitehouse AJ, Gilani SZ, Shafait F, Mian A, Tan DW, Maybery MT, Keelan JA, Hart R, Handelsman DJ, Goonawardene M, Eastwood P** 2015 Prenatal testosterone exposure is related to sexually dimorphic facial morphology in adulthood. *Proc Biol Sci* 282:20151351
82. **Aksglaede L, Andersson AM, Jorgensen N, Jensen TK, Carlsen E, McLachlan RI, Skakkebaek NE, Petersen JH, Juul A** 2007 Primary testicular failure in Klinefelter's syndrome: the use of bivariate luteinizing hormone-testosterone reference charts. *Clin Endocrinol (Oxf)* 66:276-281
83. **Lue Y, Rao PN, Sinha Hikim AP, Im M, Salameh WA, Yen PH, Wang C, Swerdloff RS** 2001 XXY male mice: an experimental model for Klinefelter syndrome. *Endocrinology* 142:1461-1470
84. **Wistuba J, Luetjens CM, Stukenborg JB, Poplinski A, Werler S, Dittmann M, Damm OS, Hamalainen T, Simoni M, Gromoll J** 2010 Male 41, XXY* mice as a model for klinefelter syndrome: hyperactivation of leydig cells. *Endocrinology* 151:2898-2910
85. **Boisen E** 1979 Testicular size and shape of 47,XYY and 47,XXY men in a double-blind, double-matched population survey. *Am J Hum Genet* 31:697-703
86. **Close S, Fennoy I, Smaldone A, Reame N** 2015 Phenotype and Adverse Quality of Life in Boys with Klinefelter Syndrome. *J Pediatr* 167:650-657
87. **Zitzmann M, Bongers R, Werler S, Bogdanova N, Wistuba J, Kliesch S, Gromoll J, Tüttelmann F** 2015 Gene expression patterns in relation to the clinical phenotype in Klinefelter syndrome. *J Clin Endocrinol Metab* 100:E518-E523
88. **Smyth CM, Bremner WJ** 1998 Klinefelter syndrome. *Arch Intern Med* 158:1309-1314
89. **Bardsley MZ, Falkner B, Kowal K, Ross JL** 2011 Insulin resistance and metabolic syndrome in prepubertal boys with Klinefelter syndrome. *Acta Paediatr* 100:866-870
90. **Aksglaede L, Skakkebaek NE, Almstrup K, Juul A** 2011 Clinical and biological parameters in 166 boys, adolescents and adults with nonmosaic Klinefelter syndrome: a Copenhagen experience. *Acta Paediatr* 100:793-806
91. **Kamischke A, Baumgardt A, Horst J, Nieschlag E** 2003 Clinical and diagnostic features of patients with suspected Klinefelter syndrome. *J Androl* 24:41-48
92. **Maseroli E, Rastrelli G, Corona G, Boddi V, Amato AM, Mannucci E, Forti G, Maggi M** 2014 Gynecomastia in subjects with sexual dysfunction. *J Endocrinol Invest* 37:525-532
93. **Paris F, Gaspari L, Mbou F, Philibert P, Audran F, Morel Y, Bignon-Laubert A, Sultan C** 2016 Endocrine and molecular investigations in a cohort of 25 adolescent males with prominent/persistent pubertal gynecomastia. *Andrology* 4:263-269
94. **Sher ES, Migeon CJ, Berkovitz GD** 1998 Evaluation of boys with marked breast development at puberty. *Clin Pediatr (Phila)* 37:367-371
95. **Han SJ, Kim KS, Kim W, Kim JH, Lee YH, Nam JS, Seo JA, Kim BK, Lee J, Chung JO, Kim MH, Sohn TS, Choi HS, Hong SB, Chung YS** 2016 Obesity and Hyperglycemia in Korean Men with Klinefelter Syndrome: The Korean Endocrine Society Registry. *Endocrinol Metab (Seoul)* 31:598-603

96. **Aksglaede L, Molgaard C, Skakkebaek NE, Juul A** 2008 Normal bone mineral content but unfavourable muscle/fat ratio in Klinefelter syndrome. *Arch Dis Child* 93:30-34
97. **Jo DG, Lee HS, Joo YM, Seo JT** 2013 Effect of testosterone replacement therapy on bone mineral density in patients with Klinefelter syndrome. *Yonsei Med J* 54:1331-1335
98. **Pasquali D, Arcopinto M, Renzullo A, Rotondi M, Accardo G, Salzano A, Esposito D, Saldamarco L, Isidori AM, Marra AM, Ruvolo A, Napoli R, Bossone E, Lenzi A, Baliga RR, Sacca L, Cittadini A** 2012 Cardiovascular abnormalities in Klinefelter Syndrome. *Int J Cardiol* 168:754-759
99. **Davis SM, Cox-Martin MG, Bardsley MZ, Kowal K, Zeitler PS, Ross JL** 2017 Effects of Oxandrolone on Cardiometabolic Health in Boys With Klinefelter Syndrome: A Randomized Controlled Trial. *J Clin Endocrinol Metab* 102:176-184
100. **Schiffer L, Kempegowda P, Arlt W, O'Reilly MW** 2017 MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease. *Eur J Endocrinol* EJE-0124
101. **Bojesen A, Gravholt CH** 2007 Klinefelter syndrome in clinical practice. *Nat Clin Pract Urol* 4:192-204
102. **Host C, Gormsen LC, Hougaard DM, Christiansen JS, Pedersen SB, Gravholt CH** 2014 Acute and short-term chronic testosterone fluctuation effects on glucose homeostasis, insulin sensitivity, and adiponectin: a randomized, double-blind, placebo-controlled, crossover study. *J Clin Endocrinol Metab* 99:E1088-E1096
103. **Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ** 2007 Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. *J Clin Endocrinol Metab* 92:4254-4259
104. **Bojesen A, Host C, Gravholt CH** 2010 Klinefelter's syndrome, type 2 diabetes and the metabolic syndrome: the impact of body composition. *Mol Hum Reprod* 16:396-401
105. **Lin T, Haskell J, Vinson N, Terracio L** 1986 Characterization of insulin and insulin-like growth factor I receptors of purified Leydig cells and their role in steroidogenesis in primary culture: a comparative study. *Endocrinology* 119:1641-1647
106. **Pitteloud N, Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi D, Hayes FJ** 2005 Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. *J Clin Endocrinol Metab* 90:2636-2641
107. **Ross JL, Zeger MP, Kushner H, Zinn AR, Roeltgen DP** 2009 An extra X or Y chromosome: contrasting the cognitive and motor phenotypes in childhood in boys with 47,XXX syndrome or 47,XXY Klinefelter syndrome. *Dev Disabil Res Rev* 15:309-317
108. **Harlow TL, Gonzalez-Alegre P** 2009 High prevalence of reported tremor in Klinefelter syndrome. *Parkinsonism Relat Disord* 15:393-395
109. **Bojesen A, Birkebaek N, Kristensen K, Heickendorff L, Mosekilde L, Christiansen JS, Gravholt CH** 2011 Bone mineral density in Klinefelter syndrome is reduced and primarily determined by muscle strength and resorptive markers, but not directly by testosterone. *Osteoporos Int* 22:1441-1450
110. **Salbenblatt JA, Meyers DC, Bender BG, Linden MG, Robinson A** 1987 Gross and fine motor development in 47,XXY and 47,XYY males. *Pediatrics* 80:240-244
111. **Ross JL, Kushner H, Kowal K, Bardsley M, Davis S, Reiss AL, Tartaglia N, Roeltgen D** 2017 Androgen Treatment Effects on Motor Function, Cognition, and Behavior in Boys with Klinefelter Syndrome. *J Pediatr* 10

112. **Host C, Bojesen A, Frystyk J, Flyvbjerg A, Christiansen JS, Gravholt CH** 2010 Effect of sex hormone treatment on circulating adiponectin and subforms in Turner and Klinefelter syndrome. *Eur J Clin Invest* 40:211-219
113. **Pei D, Sheu WH, Jeng CY, Liao WK, Fuh MM** 1998 Insulin resistance in patients with Klinefelter's syndrome and idiopathic gonadotropin deficiency. *J Formos Med Assoc* 97:534-540
114. **Selice R, Caretta N, Di MA, Torino M, Palego P, Ferlin A, Foresta C** 2013 Prostate volume and growth during testosterone replacement therapy is related to visceral obesity in Klinefelter syndrome. *Eur J Endocrinol* 169:743-749
115. **Yesilova Z, Oktenli C, Sanisoglu SY, Musabak U, Cakir E, Ozata M, Dagalp K** 2005 Evaluation of insulin sensitivity in patients with Klinefelter's syndrome: a hyperinsulinemic euglycemic clamp study. *Endocrine* 27:11-16
116. **Jiang-Feng M, Hong-Li X, Xue-Yan W, Min N, Shuang-Yu L, Hong-Ding X, Liang-Ming L** 2012 Prevalence and risk factors of diabetes in patients with Klinefelter syndrome: a longitudinal observational study. *Fertil Steril* 98:1331-1335
117. **Host C, Skakkebaek A, Groth KA, Bojesen A** 2014 The role of hypogonadism in Klinefelter syndrome. *Asian J Androl* 16:185-191
118. **Ozata M, Ozisik G, Caglayan S, Yesilova Z, Bingol N, Saglam M, Turan M, Beyhan Z** 1998 Effects of gonadotropin and testosterone treatments on plasma leptin levels in male patients with idiopathic hypogonadotropic hypogonadism and Klinefelter's syndrome. *Horm Metab Res* 30:266-271
119. **Pagotto U, Gambineri A, Pelusi C, Genghini S, Cacciari M, Otto B, Castaneda T, Tschop M, Pasquali R** 2003 Testosterone replacement therapy restores normal ghrelin in hypogonadal men. *J Clin Endocrinol Metab* 88:4139-4143
120. **Rotondi M, Coperchini F, Renzullo A, Accardo G, Esposito D, Groppelli G, Magri F, Cittadini A, Isidori AM, Chiovato L, Pasquali D** 2014 High circulating levels of CCL2 in patients with Klinefelter's syndrome. *Clin Endocrinol (Oxf)* 80:465-467
121. **Ishikawa T, Yamaguchi K, Kondo Y, Takenaka A, Fujisawa M** 2008 Metabolic syndrome in men with Klinefelter's syndrome. *Urology* 71:1109-1113
122. **Overvad S, Bay K, Bojesen A, Gravholt CH** 2014 Low INSL3 in Klinefelter syndrome is related to osteocalcin, testosterone treatment and body composition, as well as measures of the hypothalamic-pituitary-gonadal axis. *Andrology* 2:421-427
123. **Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT** 2004 Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. *Diabetes Care* 27:1036-1041
124. **Panimolle F, Tiberti C, Granato S, Semeraro A, Gianfrilli D, Anzuini A, Lenzi A, Radicioni A** 2016 Screening of endocrine organ-specific humoral autoimmunity in 47,XXY Klinefelter's syndrome reveals a significant increase in diabetes-specific immunoreactivity in comparison with healthy control men. *Endocrine* 52:157-164
125. **Jones DB, Higgins B, Billet JS, Price WH, Edwards CR, Beastall GH, Shepherd J, Sweeting VM, Horn DB, Wenham PR** 1989 The effect of testosterone replacement on plasma lipids and apolipoproteins. *Eur J Clin Invest* 19:438-441
126. **Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM** 2010 Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 95:2536-2559
127. **Basaria S** 2014 Male hypogonadism. *Lancet* 383:1250-1263

128. **Mortensen KH, Andersen NH, Gravholt CH** 2012 Cardiovascular phenotype in Turner syndrome--integrating cardiology, genetics, and endocrinology. *Endocr Rev* 33:677-714
129. **Agarwal S, Dekam MJ** 2011 Multiple cardiac anomalies in an elderly man with Klinefelter's syndrome. *Singapore Med J* 52:e15-e17
130. **Karagoz A, Dikbas O, Teker E, Vural A, Gunaydin ZY, Bektas O** 2015 Sinus node dysfunction requiring permanent pacemaker implantation in a young adult with Klinefelter syndrome. *Am J Case Rep* 16:136-9. doi: 10.12659/AJCR.893065.:136-139
131. **Okayama S, Uemura S, Saito Y** 2013 Hypertrophic cardiomyopathy and mesenteric venous thrombosis in a patient with Klinefelter syndrome. *Int J Cardiol* 166:e50-e52
132. **Rosenthal A** 1972 Cardiovascular malformations in Klinefelter's syndrome: report of three cases. *J Pediatr* 80:471-473
133. **Yoshida K, Ryu T, Ogata T, Tsuji S, Tokushima T, Utsunomiya T, Matsuo S** 1998 An elderly man with Klinefelter syndrome associated with hypertrophic cardiomyopathy, sick sinus syndrome, and coronary arteriovenous fistula. *Jpn Circ J* 62:222-224
134. **Fricke GR, Mattern HJ, Schweikert HU** 1981 Mitral valve prolapse in Klinefelter syndrome. *Lancet* %19-26;2:1414
135. **Fricke GR, Mattern HJ, Schweikert HU, Schwanitz G** 1984 Klinefelter's syndrome and mitral valve prolapse. an echocardiographic study in twenty-two patients. *Biomed Pharmacother* 38:88-97
136. **Andersen NH, Bojesen A, Kristensen K, Birkebaek NH, Fedder J, Bennett P, Christiansen JS, Gravholt CH** 2008 Left ventricular dysfunction in Klinefelter syndrome is associated to insulin resistance, abdominal adiposity and hypogonadism. *Clin Endocrinol (Oxf)* 69:785-791
137. **Jorgensen IN, Skakkebaek A, Andersen NH, Pedersen LN, Hougaard DM, Bojesen A, Trolle C, Gravholt CH** 2015 Short QTc Interval in Males with Klinefelter Syndrome-Influence of CAG Repeat Length, Body Composition, and Testosterone Replacement Therapy. *Pacing Clin Electrophysiol* 38:472-482
138. **Sedlak T, Shufelt C, Iribarren C, Merz CN** 2012 Sex hormones and the QT interval: a review. *J Womens Health (Larchmt)* 21:933-941
139. **Kelly DM, Jones TH** 2013 Testosterone: a vascular hormone in health and disease. *J Endocrinol* 217:R47-R71
140. **Foresta C, Caretta N, Palego P, Ferlin A, Zuccarello D, Lenzi A, Selice R** 2012 Reduced artery diameters in Klinefelter syndrome. *Int J Androl* 35:720-725
141. **Di MA, Ferlin A, De TL, Selice R, Caretta N, Foresta C** 2010 Endothelial progenitor cells as a new cardiovascular risk factor in Klinefelter's syndrome. *Mol Hum Reprod* 16:411-417
142. **Budoff MJ, Ellenberg SS, Lewis CE, Mohler ER, III, Wenger NK, Bhasin S, Barrett-Connor E, Swerdloff RS, Stephens-Shields A, Cauley JA, Crandall JP, Cunningham GR, Ensrud KE, Gill TM, Matsumoto AM, Molitch ME, Nakanishi R, Nezarat N, Matsumoto S, Hou X, Basaria S, Diem SJ, Wang C, Cifelli D, Snyder PJ** 2017 Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. *JAMA* 317:708-716
143. **Andersen NH, Bojesen A, Christiansen JS, Gravholt CH** 2008 Glycemia, lipidemia and systolic left ventricular function evaluated by myocardial strain rate: a tissue Doppler echocardiographic study. *Ultrasound Med Biol* 34:151-154

144. **Di Minno MN, Esposito D, Di MA, Accardo G, Lupoli G, Cittadini A, Giugliano D, Pasquali D** 2015 Increased platelet reactivity in Klinefelter men: something new to consider. *Andrology* 3:876-881
145. **Campbell WA, Newton MS, Price WH** 1980 Hypostatic leg ulceration and Klinefelter's syndrome. *J Ment Defic Res* 24:115-117
146. **Campbell WA, Price WH** 1981 Venous thromboembolic disease in Klinefelter's syndrome. *Clin Genet* 19:275-280
147. **Tagalakakis V, Patenaude V, Kahn SR, Suissa S** 2013 Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. *Am J Med* 126:832-21
148. **Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Hansen JB** 2010 Hematocrit and risk of venous thromboembolism in a general population. The Tromso study. *Haematologica* 95:270-275
149. **Sidelmann JJ, Gram J, Jespersen J, Kluft C** 2000 Fibrin clot formation and lysis: basic mechanisms. *Semin Thromb Hemost* 26:605-618
150. **Caron P, Bennet A, Camare R, Louvet JP, Boneu B, Sie P** 1989 Plasminogen activator inhibitor in plasma is related to testosterone in men. *Metabolism* 38:1010-1015
151. **De PG, De M, V, Sciaraffia M, Pannacciulli N, Minenna A, Giorgino F, Petronelli M, Laudadio E, Giorgino R** 1997 Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men. *Metabolism* 46:1287-1293
152. **Zollner TM, Veraart JC, Wolter M, Hesse S, Villemur B, Wenke A, Werner RJ, Boehncke WH, Jost SS, Scharrer I, Kaufmann R** 1997 Leg ulcers in Klinefelter's syndrome--further evidence for an involvement of plasminogen activator inhibitor-1. *Br J Dermatol* 136:341-344
153. **Glueck CJ, Jetty V, Goldenberg N, Shah P, Wang P** 2016 Thrombophilia in Klinefelter Syndrome With Deep Venous Thrombosis, Pulmonary Embolism, and Mesenteric Artery Thrombosis on Testosterone Therapy. *Clin Appl Thromb Hemost* 1076029616665923
154. **Price WH, Clayton JF, Wilson J, Collyer S, De MR** 1985 Causes of death in X chromatin positive males (Klinefelter's syndrome). *J Epidemiol Community Health* 39:330-336
155. **Chang S, Larsen OH, Skakkebaek A, Bojesen A, Gravholt CH, Bor V** Platelet aggregation is not increased in testosterone treatment naive Klinefelter syndrome. (Abstract)
156. **Yesilova Z, Ozata M, Oktenli C, Sanisoglu SY, Erbil MK, Dagalp K** 2004 Effect of supraphysiologic doses of testosterone on fasting plasma total homocysteine concentrations in men with Klinefelter's syndrome. *Fertil Steril* 81:1278-1282
157. **Ferlin A, Schipilliti M, Vinanzi C, Garolla A, Di MA, Selice R, Lenzi A, Foresta C** 2011 Bone mass in subjects with Klinefelter syndrome: role of testosterone levels and androgen receptor gene CAG polymorphism. *J Clin Endocrinol Metab* 96:E739-E745
158. **Ferlin A, Selice R, Di MA, Ghezzi M, Di NA, Caretta N, Foresta C** 2015 Role of vitamin D levels and vitamin D supplementation on bone mineral density in Klinefelter syndrome. *Osteoporos Int* 26:2193-2202
159. **Shanbhogue VV, Hansen S, Jorgensen NR, Brixen K, Gravholt CH** 2014 Bone Geometry, Volumetric Density, Microarchitecture and Estimated Bone Strength Assessed by HR-pQCT in Klinefelter Syndrome. *J Bone Miner Res* 29:2474-2482

160. **Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E** 1997 Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. *J Clin Endocrinol Metab* 82:2386-2390
161. **van den Bergh JP, Hermus AR, Spruyt AI, Sweep CG, Corstens FH, Smals AG** 2001 Bone mineral density and quantitative ultrasound parameters in patients with Klinefelter's syndrome after long-term testosterone substitution. *Osteoporos Int* 12:55-62
162. **Liu PY, Kalak R, Lue Y, Jia Y, Erkkila K, Zhou H, Seibel MJ, Wang C, Swerdloff RS, Dunstan CR** 2010 Genetic and hormonal control of bone volume, architecture, and remodeling in XXY mice. *J Bone Miner Res* 25:2148-2154
163. **Seminog OO, Seminog AB, Yeates D, Goldacre MJ** 2015 Associations between Klinefelter's syndrome and autoimmune diseases: English national record linkage studies. *Autoimmunity* 48:125-128
164. **Lleo A, Moroni L, Caliari L, Invernizzi P** 2012 Autoimmunity and Turner's syndrome. *Autoimmun Rev* 11:A538-A543
165. **Scofield RH, Bruner GR, Namjou B, Kimberly RP, Ramsey-Goldman R, Petri M, Reveille JD, Alarcon GS, Vila LM, Reid J, Harris B, Li S, Kelly JA, Harley JB** 2008 Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: Support for the notion of a gene-dose effect from the X chromosome. *Arthritis Rheum* 58:2511-2517
166. **Sawalha AH, Harley JB, Scofield RH** 2009 Autoimmunity and Klinefelter's syndrome: when men have two X chromosomes. *J Autoimmun* 33:31-34
167. **Ferlin A, Arredi B, Foresta C** 2006 Genetic causes of male infertility. *Reprod Toxicol* 22:133-141
168. **Laron Z, Dickerman Z, Zamir R, Galatzer A** 1982 Paternity in Klinefelter's syndrome--a case report. *Arch Androl* 8:149-151
169. **Cruger D, Toft B, Agerholm I, Fedder J, Hald F, Bruun-Petersen G** 2001 Birth of a healthy girl after ICSI with ejaculated spermatozoa from a man with non-mosaic Klinefelter's syndrome. *Hum Reprod* 16:1909-1911
170. **Kitamura M, Matsumiya K, Koga M, Nishimura K, Miura H, Tsuji T, Matsumoto M, Okamoto Y, Okuyama A** 2000 Ejaculated spermatozoa in patients with non-mosaic Klinefelter's syndrome. *Int J Urol* 7:88-92
171. **Maiburg M, Repping S, Giltay J** 2012 The genetic origin of Klinefelter syndrome and its effect on spermatogenesis. *Fertil Steril* 98:253-260
172. **Sciurano RB, Luna Hisano CV, Rahn MI, Brugo OS, Rey VG, Coco R, Solari AJ** 2009 Focal spermatogenesis originates in euploid germ cells in classical Klinefelter patients. *Hum Reprod* 24:2353-2360
173. **Tuttelmann F, Damm OS, Luetjens CM, Baldi M, Zitzmann M, Kliesch S, Nieschlag E, Gromoll J, Wistuba J, Simoni M** 2014 Intratesticular testosterone is increased in men with Klinefelter syndrome and may not be released into the bloodstream owing to altered testicular vascularization- a preliminary report. *Andrology* 2:275-281
174. **Hirota T, Ohta H, Powell BE, Mahadevaiah SK, Ojarikre OA, Saitou M, Turner JMA** 2017 Fertile offspring from sterile sex chromosome trisomic mice. *Science* eam9046
175. **D'Aurora M, Ferlin A, Garolla A, Franchi S, D'Onofrio L, Trubiani O, Palka G, Foresta C, Stuppia L, Gatta V** 2017 Testis Transcriptome Modulation in Klinefelter Patients with Hypospermatogenesis. *Sci Rep* 7:45729. doi: 10.1038/srep45729.:45729
176. **Wikstrom AM, Raivio T, Hadziselimovic F, Wikstrom S, Tuuri T, Dunkel L** 2004 Klinefelter syndrome in adolescence: onset of puberty is associated with accelerated germ cell depletion. *J Clin Endocrinol Metab* 89:2263-2270

177. **Winge SB, Dalgaard MD, Jensen JM, Graem N, Schierup MH, Juul A, Rajpert-De ME, Almstrup K** 2017 Transcriptome profiling of fetal Klinefelter testis tissue reveals a possible involvement of long non-coding RNAs in gonocyte maturation. *Hum Mol Genet* 46:57098
178. **Greco E, Scarselli F, Minasi MG, Casciani V, Zavaglia D, Dente D, Tesarik J, Franco G** 2013 Birth of 16 healthy children after ICSI in cases of nonmosaic Klinefelter syndrome. *Hum Reprod* 28:1155-1160
179. **Schlegel PN, Su LM** 1997 Physiological consequences of testicular sperm extraction. *Hum Reprod* 12:1688-1692
180. **Schlegel PN** 1999 Testicular sperm extraction: microdissection improves sperm yield with minimal tissue excision. *Hum Reprod* 14:131-135
181. **Colpi GM, Colpi EM, Piediferro G, Giacchetta D, Gazzano G, Castiglioni FM, Magli MC, Gianaroli L** 2009 Microsurgical TESE versus conventional TESE for ICSI in non-obstructive azoospermia: a randomized controlled study. *Reprod Biomed Online* 18:315-319
182. **Fullerton G, Hamilton M, Maheshwari A** 2010 Should non-mosaic Klinefelter syndrome men be labelled as infertile in 2009? *Hum Reprod*
183. **Ramasamy R, Ricci JA, Palermo GD, Gosden LV, Rosenwaks Z, Schlegel PN** 2009 Successful fertility treatment for Klinefelter's syndrome. *J Urol* 182:1108-1113
184. **Fedder J, Gravholt CH, Kristensen SG, Marcussen N, Engvad B, Milton AM, Andersen CY** 2015 Testicular Sperm Sampling by Subcapsular Orchiectomy in Klinefelter Patients: A New Simplified Treatment Approach. *Urology* 86:744-750
185. **Westlander G, Ekerhovd E, Bergh C** 2003 Low levels of serum inhibin B do not exclude successful sperm recovery in men with nonmosaic Klinefelter syndrome. *Fertil Steril* 79 Suppl 3:1680-2:1680-1682
186. **Takada S, Tsujimura A, Ueda T, Matsuoka Y, Takao T, Miyagawa Y, Koga M, Takeyama M, Okamoto Y, Matsumiya K, Fujioka H, Nonomura N, Okuyama A** 2008 Androgen decline in patients with nonobstructive azoospermia after microdissection testicular sperm extraction. *Urology* 72:114-118
187. **Ishikawa T, Yamaguchi K, Chiba K, Takenaka A, Fujisawa M** 2009 Serum hormones in patients with nonobstructive azoospermia after microdissection testicular sperm extraction. *J Urol* 182:1495-1499
188. **Gies I, De SJ, Van SD, Anckaert E, Goossens E, Tournaye H** 2012 Failure of a combined clinical- and hormonal-based strategy to detect early spermatogenesis and retrieve spermatogonial stem cells in 47,XXY boys by single testicular biopsy. *Hum Reprod* 27:998-1004
189. **Van SD, Gies I, De SJ, Tournaye H, Goossens E** 2012 Can pubertal boys with Klinefelter syndrome benefit from spermatogonial stem cell banking? *Hum Reprod* 27:323-330
190. **Rives N, Milazzo JP, Perdrix A, Castanet M, Joly-Helas G, Sibert L, Bironneau A, Way A, Mace B** 2013 The feasibility of fertility preservation in adolescents with Klinefelter syndrome. *Hum Reprod* 28:1468-1479
191. **Mehta A, Bolyakov A, Roosma J, Schlegel PN, Paduch DA** 2013 Successful testicular sperm retrieval in adolescents with Klinefelter syndrome treated with at least 1 year of topical testosterone and aromatase inhibitor. *Fertil Steril* 100:970-974
192. **Plotton I, Giscard dS, Cuzin B, Brosse A, Benchaib M, Lornage J, Ecochard R, Dijoud F, Lejeune H** 2015 Preliminary results of a prospective study of testicular sperm extraction in young versus adult patients with nonmosaic 47,XXY Klinefelter syndrome. *J Clin Endocrinol Metab* 100:961-967

193. **Gies I, Oates R, De SJ, Tournaye H** 2016 Testicular biopsy and cryopreservation for fertility preservation of prepubertal boys with Klinefelter syndrome: a pro/con debate. *Fertil Steril* 105:249-255
194. **Gies I, Tournaye H, De SJ** 2016 Attitudes of parents of Klinefelter boys and pediatricians towards neonatal screening and fertility preservation techniques in Klinefelter syndrome. *Eur J Pediatr* 175:399-404
195. **Ron-El R, Strassburger D, Gelman-Kohan S, Friedler S, Raziel A, Appelman Z** 2000 A 47,XXY fetus conceived after ICSI of spermatozoa from a patient with non-mosaic Klinefelter's syndrome: case report. *Hum Reprod* 15:1804-1806
196. **Lewejohann L, Damm OS, Luetjens CM, Hamalainen T, Simoni M, Nieschlag E, Gromoll J, Wistuba J** 2009 Impaired recognition memory in male mice with a supernumerary X chromosome. *Physiol Behav* 96:23-29
197. **Werler S, Demond H, Damm OS, Ehmcke J, Middendorff R, Gromoll J, Wistuba J** 2014 Germ cell loss is associated with fading Lin28a expression in a mouse model for Klinefelter's syndrome. *Reproduction* 147:253-264
198. **Wistuba J** 2010 Animal models for Klinefelter's syndrome and their relevance for the clinic. *Mol Hum Reprod* 16:375-385
199. **Corona G, Petrone L, Paggi F, Lotti F, Boddi V, Fisher A, Vignozzi L, Balercia G, Sforza A, Forti G, Mannucci E, Maggi M** 2010 Sexual dysfunction in subjects with Klinefelter's syndrome. *Int J Androl* 33:574-580
200. **Yoshida A, Miura K, Nagao K, Hara H, Ishii N, Shirai M** 1997 Sexual function and clinical features of patients with Klinefelter's syndrome with the chief complaint of male infertility. *Int J Androl* 20:80-85
201. **El BH, Majzoub A, Al SS, Alnawasra H, Dabbous Z, Arafa M** 2016 Sexual dysfunction in Klinefelter's syndrome patients. *Andrologia* 10
202. **Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M** 2004 The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. *Curr Med Res Opin* 20:607-617
203. **Skakkebaek A, Moore PJ, Chang S, Fedder J, Gravholt CH** 2017 Quality of life in men with Klinefelter syndrome: the impact of genotype, health, socioeconomics, and sexual function. *Genet Med* 10
204. **Feldman HA, Johannes CB, Derby CA, Kleinman KP, Mohr BA, Araujo AB, McKinlay JB** 2000 Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. *Prev Med* 30:328-338
205. **Kasturi SS, Tannir J, Brannigan RE** 2008 The metabolic syndrome and male infertility. *J Androl* 29:251-259
206. **Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB** 1994 Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. *J Urol* 151:54-61
207. **Wu FC, Bancroft J, Davidson DW, Nicol K** 1982 The behavioural effects of testosterone undecanoate in adult men with Klinefelter's syndrome: a controlled study. *Clin Endocrinol (Oxf)* 16:489-497
208. **Skakkebaek NE, Bancroft J, Davidson DW, Warner P** 1981 Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. *Clin Endocrinol (Oxf)* 14:49-61
209. **Wang C, Swedloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N** 2000 Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. *J Clin Endocrinol Metab* 85:2839-2853

210. **Raboch J, Pietrucha S, Raboch J** 2003 Serum testosterone levels and coital activity in men with somatosexual disorders. *Neuro Endocrinol Lett* 24:321-324
211. **Stochholm K, Bojesen A, Jensen AS, Juul S, Gravholt CH** 2012 Criminality in men with Klinefelter's syndrome and XYY syndrome: a cohort study. *BMJ Open* 2:e000650
212. **Fisher AD, Castellini G, Casale H, Fanni E, Bandini E, Campone B, Ferruccio N, Maseroli E, Boddi V, Dettore D, Pizzocaro A, Balercia G, Oppo A, Ricca V, Maggi M** 2015 Hypersexuality, Paraphilic Behaviors, and Gender Dysphoria in Individuals with Klinefelter's Syndrome. *J Sex Med* 12:2413-2424
213. **Davies GW, Parkinson J** 2017 Gender dysphoria in Klinefelter's syndrome: three cases. *Australas Psychiatry* 1039856217715986
214. **Geschwind DH, Gregg J, Boone K, Karrim J, Pawlikowska-Haddal A, Rao E, Ellison J, Ciccodicola A, D'Urso M, Woods R, Rappold GA, Swerdloff R, Nelson SF** 1998 Klinefelter's syndrome as a model of anomalous cerebral laterality: testing gene dosage in the X chromosome pseudoautosomal region using a DNA microarray. *Dev Genet* 23:215-229
215. **Netley C, Rovet J** 1982 Verbal deficits in children with 47,XXY and 47,XXX karyotypes: a descriptive and experimental study. *Brain Lang* 17:58-72
216. **Ratcliffe SG, Masera N, Pan H, McKie M** 1994 Head circumference and IQ of children with sex chromosome abnormalities. *Dev Med Child Neurol* 36:533-544
217. **van RS, Swaab H** 2015 Executive dysfunction and the relation with behavioral problems in children with 47,XXY and 47,XXX. *Genes Brain Behav* 14:200-208
218. **Bender BG, Puck MH, Salbenblatt JA, Robinson A** 1986 Dyslexia in 47,XXY boys identified at birth. *Behav Genet* 16:343-354
219. **Ratcliffe SG, Butler GE, Jones M** 1990 Edinburgh study of growth and development of children with sex chromosome abnormalities. IV. Birth Defects Orig Artic Ser 26:1-44
220. **Pennington BF, Bender B, Puck M, Salbenblatt J, Robinson A** 1982 Learning disabilities in children with sex chromosome anomalies. *Child Dev* 53:1182-1192
221. **Samango-Sprouse C** 2001 Mental development in polysomy X Klinefelter syndrome (47,XXY; 48,XXXY): effects of incomplete X inactivation. *Semin Reprod Med* 19:193-202
222. **Bender BG, Linden MG, Robinson A** 1989 Verbal and spatial processing efficiency in 32 children with sex chromosome abnormalities. *Pediatr Res* 25:577-579
223. **Bender BG, Linden MG, Harmon RJ** 2001 Neuropsychological and functional cognitive skills of 35 unselected adults with sex chromosome abnormalities. *Am J Med Genet* 102:309-313
224. **Boone KB, Swerdloff RS, Miller BL, Geschwind DH, Razani J, Lee A, Gonzalo IG, Haddal A, Rankin K, Lu P, Paul L** 2001 Neuropsychological profiles of adults with Klinefelter syndrome. *J Int Neuropsychol Soc* 7:446-456
225. **Ratcliffe SG** 1982 Speech and learning disorders in children with sex chromosome abnormalities. *Dev Med Child Neurol* 24:80-84
226. **Boada R, Janusz J, Hutaff-Lee C, Tartaglia N** 2009 The cognitive phenotype in Klinefelter syndrome: a review of the literature including genetic and hormonal factors. *Dev Disabil Res Rev* 15:284-294
227. **Hong DS, Reiss AL** 2014 Cognitive and neurological aspects of sex chromosome aneuploidies. *Lancet Neurol* 13:306-318
228. **Verri A, Cremante A, Clerici F, Destefani V, Radicioni A** 2010 Klinefelter's syndrome and psychoneurologic function. *Mol Hum Reprod* 16:425-433

229. **Geschwind D, Dykens E** 2004 Neurobehavioral and psychosocial issues in Klinefelter syndrome. *Learn Dis Res Pract* 19:166-173
230. **Bender BG, Linden MG, Robinson A** 1993 Neuropsychological impairment in 42 adolescents with sex chromosome abnormalities. *Am J Med Genet* 48:169-173
231. **Graham JM, Jr., Bashir AS, Stark RE, Silbert A, Walzer S** 1988 Oral and written language abilities of XXY boys: implications for anticipatory guidance. *Pediatrics* 81:795-806
232. **Walzer S, Bashir AS, Silbert AR** 1990 Cognitive and behavioral factors in the learning disabilities of 47,XXY and 47,XYY boys. *Birth Defects Orig Artic Ser* 26:45-58
233. **Mazzocco MM, Ross JL** 2007 When a genetic disorder is associated with learning disabilities: variation of manifestation in childhood. In: Mazzocco MM, Ross JL, eds. *Neurogenetic developmental disorders: variation of manifestation in childhood*. Cambridge, MA: MIT Press; 415-436
234. **Rovet J, Netley C, Keenan M, Bailey J, Stewart D** 1996 The psychoeducational profile of boys with Klinefelter syndrome. *J Learn Disabil* 29:180-196
235. **Peterson RL, Pennington BF** 2012 Developmental dyslexia. *Lancet* 379:1997-2007
236. **Robinson A, Lubs HA, Nielsen J, Sorensen K** 1979 Summary of clinical findings: profiles of children with 47,XXY, 47,XXX and 47,XYY karyotypes. *Birth Defects Orig Artic Ser* 15:261-266
237. **Bancroft J, Axworthy D, Ratcliffe S** 1982 The personality and psychosexual development of boys with 47 XXY chromosome constitution. *J Child Psychol Psychiatry* 23:169-180
238. **Kompus K, Westerhausen R, Nilsson LG, Hugdahl K, Jongstra S, Berglund A, Arver S, Savic I** 2011 Deficits in inhibitory executive functions in Klinefelter (47, XXY) syndrome. *Psychiatry Res* 189:135-140
239. **Temple CM, Sanfilippo PM** 2003 Executive skills in Klinefelter's syndrome. *Neuropsychologia* 41:1547-1559
240. **Fales CL, Knowlton BJ, Holyoak KJ, Geschwind DH, Swerdloff RS, Gonzalo IG** 2003 Working memory and relational reasoning in Klinefelter syndrome. *J Int Neuropsychol Soc* 9:839-846
241. **Skakkebaek A, Moore PJ, Pedersen AD, Bojesen A, Kristensen MK, Fedder J, Laurberg P, Hertz JM, Ostergaard JR, Wallentin M, Gravholt CH** 2017 The role of genes, intelligence, personality, and social engagement in cognitive performance in Klinefelter syndrome. *Brain Behav* 7:e00645
242. **Lue Y, Jentsch JD, Wang C, Rao PN, Hikim AP, Salameh W, Swerdloff RS** 2005 XXY mice exhibit gonadal and behavioral phenotypes similar to Klinefelter syndrome. *Endocrinology* 146:4148-4154
243. **DeLisi LE, Maurizio AM, Svetina C, Ardekani B, Szulc K, Nierenberg J, Leonard J, Harvey PD** 2005 Klinefelter's syndrome (XXY) as a genetic model for psychotic disorders. *Am J Med Genet B Neuropsychiatr Genet* 135:15-23
244. **Giedd JN, Clasen LS, Wallace GL, Lenroot RK, Lerch JP, Wells EM, Blumenthal JD, Nelson JE, Tossell JW, Stayer C, Evans AC, Samango-Sprouse CA** 2007 XXY (Klinefelter Syndrome): A Pediatric Quantitative Brain Magnetic Resonance Imaging Case-Control Study. *Pediatrics* 119:e232-e240
245. **Shen D, Liu D, Liu H, Clasen L, Giedd J, Davatzikos C** 2004 Automated morphometric study of brain variation in XXY males. *Neuroimage* 23:648-653
246. **Warwick MM, Doody GA, Lawrie SM, Kestelman JN, Best JJ, Johnstone EC** 1999 Volumetric magnetic resonance imaging study of the brain in subjects with sex chromosome aneuploidies. *J Neurol Neurosurg Psychiatry* 66:628-632

247. **Lentini E, Kasahara M, Arver S, Savic I** 2013 Sex differences in the human brain and the impact of sex chromosomes and sex hormones. *Cereb Cortex* 23:2322-2336
248. **Skakkebaek A, Gravholt CH, Rasmussen PM, Bojesen A, Jensen JT, Fedder J, Laurberg P, Hertz JM, Ostergaard JR, Pedersen AD, Wallentin M** 2013 Neuroanatomical correlates of Klinefelter syndrome studied in relation to the neuropsychological profile. *NeuroImage: Clinical* 4:1-9
249. **Bryant DM, Hoeft F, Lai S, Lackey J, Roeltgen D, Ross J, Reiss AL** 2011 Neuroanatomical phenotype of Klinefelter syndrome in childhood: a voxel-based morphometry study. *J Neurosci* 31:6654-6660
250. **Patwardhan AJ, Eliez S, Bender B, Linden MG, Reiss AL** 2000 Brain morphology in Klinefelter syndrome: extra X chromosome and testosterone supplementation. *Neurology* 54:2218-2223
251. **Goddard MN, van RS, Rombouts SA, Swaab H** 2016 White matter microstructure in a genetically defined group at increased risk of autism symptoms, and a comparison with idiopathic autism: an exploratory study. *Brain Imaging Behav* 10:1280-1288
252. **Ruigrok AN, Salimi-Khorshidi G, Lai MC, Baron-Cohen S, Lombardo MV, Tait RJ, Suckling J** 2014 A meta-analysis of sex differences in human brain structure. *Neurosci Biobehav Rev* 39:34-50. doi: 10.1016/j.neubiorev.2013.12.004. Epub@2013 Dec 26.:34-50
253. **HAMBERT G, FREY TS** 1964 The electroencephalogram in Klinefelter syndrome. *Acta Psychiatr Scand* 40:28-36.:28-36
254. **Nielsen J, Pedersen E** 1969 Electro-encephalographic findings in patients with Klinefelter's syndrome and the XYY syndrome. *Acta Neurol Scand* 45:87-94
255. **Volavka J, Mednick SA, Rasmussen L, Teasdale T** 1979 EEG response to sine wave modulated light in XYY, XXY, and XY men. *Acta Psychiatr Scand* 59:509-516
256. **Barker TE, Black FW** 1976 Klinefelter syndrome in a military population. Electroencephalographic, endocrine, and psychiatric status. *Arch Gen Psychiatry* 33:607-610
257. **Wallentin M, Skakkebaek A, Bojesen A, Fedder J, Laurberg P, Ostergaard JR, Hertz JM, Pedersen AD, Gravholt CH** 2016 Klinefelter syndrome has increased brain responses to auditory stimuli and motor output, but not to visual stimuli or Stroop adaptation. *Neuroimage Clin* 11:239-51. doi: 10.1016/j.nicl.2016.02.002. eCollection@2016.:239-251
258. **D'Esposito M, Deouell LY, Gazzaley A** 2003 Alterations in the BOLD fMRI signal with ageing and disease: a challenge for neuroimaging. *Nat Rev Neurosci* 4:863-872
259. **van Rijn S, Aleman A, Swaab H, Vink M, Sommer I, Kahn RS** 2008 Effects of an extra X chromosome on language lateralization: an fMRI study with Klinefelter men (47,XXY). *Schizophr Res* 101:17-25
260. **Brandenburg-Goddard MN, van RS, Rombouts SA, Veer IM, Swaab H** 2014 A comparison of neural correlates underlying social cognition in Klinefelter syndrome and autism. *Soc Cogn Affect Neurosci* 9:1926-1933
261. **van Rijn S, Swaab H, Baas D, de HE, Kahn RS, Aleman A** 2012 Neural systems for social cognition in Klinefelter syndrome (47,XXY): evidence from fMRI. *Soc Cogn Affect Neurosci* 7:689-697
262. **van Rijn S, Aleman A, Swaab H, Kahn RS** 2005 Neurobiology of emotion and high risk for schizophrenia: role of the amygdala and the X-chromosome. *Neurosci Biobehav Rev* 29:385-397
263. **van Rijn S, Swaab H, Aleman A, Kahn RS** 2008 Social behavior and autism traits in a sex chromosomal disorder: Klinefelter (47XXY) syndrome. *J Autism Dev Disord* 38:1634-1641

264. **Turriff A, Levy HP, Biesecker B** 2015 Factors associated with adaptation to Klinefelter syndrome: the experience of adolescents and adults. *Patient Educ Couns* 98:90-95
265. **Herlihy AS, McLachlan RI, Gillam L, Cock ML, Collins V, Halliday JL** 2011 The psychosocial impact of Klinefelter syndrome and factors influencing quality of life. *Genet Med* 13:632-642
266. **de Ronde W, de Haan A, Drent ML** 2009 Quality of life is reduced in patients with Klinefelter syndrome on androgen replacement therapy. *Eur J Endocrinol* 160:465-468
267. **Fjermestad KW, Stokke S** 2017 Sleep Problems and Life Satisfaction as Predictors of Health in Men with Sex Chromosome Aneuploidies. *Behav Med* 1-7
268. **Turriff A, Macnamara E, Levy HP, Biesecker B** 2016 The Impact of Living with Klinefelter Syndrome: A Qualitative Exploration of Adolescents and Adults. *J Genet Couns*
269. **Mackenbach JP, Karanikolos M, McKee M** 2013 The unequal health of Europeans: successes and failures of policies. *Lancet* 381:1125-1134
270. **Ratcliffe S** 1999 Long-term outcome in children of sex chromosome abnormalities. *Arch Dis Child* 80:192-195
271. **Fennoy I** 2011 Testosterone and the child (0-12 years) with Klinefelter syndrome (47XXY): a review. *Acta Paediatr* 100:846-850
272. **Kunzig HJ, Meyer U, Schmitz-Roeckerath B, Broer KH** 1977 Influence of fetal sex on the concentration of amniotic fluid testosterone: antenatal sex determination? *Arch Gynakol* 223:75-84
273. **Ross JL, Samango-Sprouse C, Lahlou N, Kowal K, Elder FF, Zinn A** 2005 Early androgen deficiency in infants and young boys with 47,XXY Klinefelter syndrome. *Horm Res* 64:39-45
274. **Lahlou N, Fennoy I, Carel JC, Roger M** 2004 Inhibin B and anti-mullerian hormone, but not testosterone levels, are normal in infants with nonmosaic klinefelter syndrome. *J Clin Endocrinol Metab* 89:1864-1868
275. **Aksglaede L, Skakkebaek NE, Juul A** 2008 Abnormal sex chromosome constitution and longitudinal growth: serum levels of insulin-like growth factor (IGF)-I, IGF binding protein-3, luteinizing hormone, and testosterone in 109 males with 47,XXY, 47,XYY, or sex-determining region of the Y chromosome (SRY)-positive 46,XX karyotypes. *J Clin Endocrinol Metab* 93:169-176
276. **Collaer ML, Geffner ME, Kaufman FR, Buckingham B, Hines M** 2002 Cognitive and behavioral characteristics of Turner syndrome: exploring a role for ovarian hormones in female sexual differentiation. *Horm Behav* 41:139-155
277. **Cooke B, Hegstrom CD, Villeneuve LS, Breedlove SM** 1998 Sexual differentiation of the vertebrate brain: principles and mechanisms. *Front Neuroendocrinol* 19:323-362
278. **McCarthy MM** 2010 How it's made: organisational effects of hormones on the developing brain. *J Neuroendocrinol* 22:736-742
279. **Neufang S, Specht K, Hausmann M, Gunturkun O, Herpertz-Dahlmann B, Fink GR, Konrad K** 2009 Sex differences and the impact of steroid hormones on the developing human brain. *Cereb Cortex* 19:464-473
280. **Samango-Sprouse CA, Sadeghin T, Mitchell FL, Dixon T, Stapleton E, Kingery M, Gropman AL** 2013 Positive effects of short course androgen therapy on the neurodevelopmental outcome in boys with 47,XXY syndrome at 36 and 72 months of age. *Am J Med Genet A* 161A:501-508

281. **Samango-Sprouse C, Stapleton EJ, Lawson P, Mitchell F, Sadeghin T, Powell S, Gropman AL** 2015 Positive effects of early androgen therapy on the behavioral phenotype of boys with 47,XXY. *Am J Med Genet C Semin Med Genet* 169:150-157
282. **Annell AL, Gustavson KH, Tenstam J** 1970 Symptomatology in schoolboys with positive sex chromatin (the klinefelter syndrome). *Acta Psychiatr Scand* 46:71-80
283. **Nielsen J, Pelsen B, Sorensen K** 1988 Follow-up of 30 Klinefelter males treated with testosterone. *Clin Genet* 33:262-269
284. **Itti E, Gaw Gonzalo IT, Pawlikowska-Haddal A, Boone KB, Mlikotic A, Itti L, Mishkin FS, Swerdloff RS** 2006 The structural brain correlates of cognitive deficits in adults with Klinefelter's syndrome. *J Clin Endocrinol Metab* 91:1423-1427
285. **Liberato D, Granato S, Grimaldi D, Rossi FM, Tahani N, Gianfrilli D, Anzuini A, Lenzi A, Cavaggioni G, Radicioni AF** 2017 Fluid intelligence, traits of personality and personality disorders in a cohort of adult KS patients with the classic 47, XXY karyotype. *J Endocrinol Invest* 10-0674
286. **Simm PJ, Zacharin MR** 2006 The psychosocial impact of Klinefelter syndrome--a 10 year review. *J Pediatr Endocrinol Metab* 19:499-505
287. **Cherrier MM, Asthana S, Plymate S, Baker L, Matsumoto AM, Peskind E, Raskind MA, Brodtkin K, Bremner W, Petrova A, Latendresse S, Craft S** 2001 Testosterone supplementation improves spatial and verbal memory in healthy older men. *Neurology* 57:80-88
288. **Rogol AD, Tartaglia N** 2010 Considerations for androgen therapy in children and adolescents with Klinefelter syndrome (47, XXY). *Pediatr Endocrinol Rev* 8 Suppl 1:145-50.:145-150

Figure 1. Age at diagnosis of 252 and 1252 pre- and postnatally diagnosed males with KS in Denmark by December 31, 2015. For comparison, diagnosed persons with additional sex chromosomes are included in the table. Based on data from Bojesen A, Juul S, Gravholt CH. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. *J Clin Endocrinol Metab* 2003; 88:622-626. The first bar (arrow) indicates the number of prenatally ascertained cases. Insert Table: in parentheses are given percentages. †The category "Born" includes all postnatal ascertained KS and all prenatal ascertained and not legally aborted KS (n=88). Some prenatally ascertained cases (n=57) were tested both prenatally and postnatally, while the remaining (n=31) were only tested prenatally. #Including 2 cases of 48,XXY,+18, 1 case with 48,XXY,+21, and one case with 48,XXY,+16. *Including 5 cases of 48,XXY,+18 and 2 cases with 2 cases of 48,XXY,+21.

Figure 2 Hazard ratios with 95% confidence intervals for ICD-10 diagnostics groups and for all diagnoses combined. Reprinted with permission from Bojesen A, Juul S, Birkebaek NH, Gravholt CH. Morbidity in Klinefelter syndrome: a Danish register study based on hospital discharge diagnoses. *J Clin Endocrinol Metab* 2006; 91:1254-1260.

Figure 3. Differentiated excess mortality in KS for all age groups (4). Categories were defined according to International Classification of Diseases version 9. Numbers are adapted to express the percentage of total absolute excess risk caused by the group of disorders in question. Includes data from Swerdlow AJ, Higgins CD, Schoemaker MJ, et al. Mortality in patients with Klinefelter syndrome in Britain: a cohort study. *J Clin Endocrinol Metab* 2005; 90:6516-6522.

Figure 4. The figure depicts the current understanding of the genomics of Klinefelter syndrome, incorporating recent genomic results. Arrows depict possible, but not proven, pathways.

Figure 5 Truncal body fat in correlation with BMI. Klinefelter syndrome patients (KS, ●) have more truncal body fat (~8% more) for any given value of BMI than control subjects (C, ○). Reproduced with permission from Bojesen A, Kristensen K, Birkebaek NH, et al. The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. *Diabetes Care* 2006; 29:1591-1598.

Figure 6 Bilateral ventral and subcortical grey matter volume in brain areas in Klinefelter syndrome. Bilateral ventral and subcortical grey matter volume in brain areas, including hippocampus, insula and striatum, is found to be smaller in KS relative to 46,XY males. A subset of KS have skewed X-chromosome inactivation. This group show an exacerbated pattern of decreased regional grey matter volume. Figure shows un-thresholded t-maps for display-purposes. Includes data from Skakkebaek A, Gravholt CH, Rasmussen PM, et al. Neuroanatomical correlates of Klinefelter syndrome studied in relation to the neuropsychological profile. *NeuroImage: Clinical* 2013; 4:1-9; and Skakkebaek A, Bojesen A, Kristensen MK, et al. Neuropsychology and brain morphology in Klinefelter syndrome - the impact of genetics. *Andrology* 201; 2:632-640.

Figure 7 The figure depicts the current understanding of the cognitive phenotype, personality profile and occurrence of psychiatric comorbidity in Klinefelter syndrome (upper part of the figure). In the lower part of the figure the more consistent changes in size of certain brain regions in Klinefelter syndrome is depicted.

Table 1 Abnormalities and diseases associated with Klinefelter syndrome

Feature	Frequency (%)
Adults	
Infertility (1)	>99
Azoospermia (1)	>95
Decreased bitesticular testis volume (4-8 ml; normal range: 25-60 ml)(2-4)	>95
Sperm after TESE	30-50
Decreased beard growth # (1)	60-80
Decreased pubic hair # (1)	30-60
Abdominal adiposity (5)	~50
Decreased muscle mass and strength (2;6)	~40
The metabolic syndrome (5)	46
Type 2 diabetes (5)	10-39
Osteopenia (6;7)	~40
Osteoporosis (6;7)	5-10
Mitral valve prolapse (8;9)	0-50
Ischemic heart disease (10;11)	~1.5 fold increased risk *
Deep venous thrombosis and pulmonary embolism (10;12;13)	3-6 fold increased risk *
Autoimmunity (14-16)	Increased risk of several autoimmune diseases
Tremor (Parkinson-like symptoms) (17;18)	>25
Breast cancer (19-21)	Increased risk (~4 fold*)
Osteoarthritis (10)	4 fold increased risk *
Children	
Learning disability (22)	>75
Delayed speech development (22)	>40
Decreased penile size (22-24)	10-25
Mediastinal cancer (25)	
All patients with Klinefelter syndrome	
Gynecomastia (2;22;26)	28-75
Cryptorchidism (3;10;22)	27-37
Increased gonadotropin levels # (1;3;4)	>75
Decreased testosterone levels # (1;3;4)	>75
Increased height (2;22)	>30
Psychiatric disturbances (22;27)	>25
Congenital malformations (heart, cleft palate and inguinal hernia)(10;13;28)	Increased risk
Fractures (10;13)	Increased risk (2-40 fold)*
Autism spectrum disorder (29;30)	30-50

TESE: testicular sperm extraction; *above normal male frequency; #in the untreated condition;

Table 2 Lipid profile in studies of Klinefelter syndrome and the effect of testosterone treatment.

REFERENC E	STUDY TYPE	N	TRIGLYCERIDES			TOTAL CHOLESTEROL			LDL CHOLESTEROL			HDL CHOLESTEROL		
			U v. T	U v. C	T v. C	U v. T	U v. C	T v. C	U v. T	U v. C	T v. C	U v. T	U v. C	T v. C
Yesilova (31)	Longitudinal prospective	32	NS	NS	-	0.011 (U↑)	NS	-	-	-	-	-	-	-
Bojesen (5)	Cross-sectional	U: 35	NS	0.0001 (U↑)	-	NS	0.002 (U↑)	-	0.04 (U↑)	0.0001 (U↑)	-	NS	0.0001 (U↓)	-
		T: 35												
Akslae (4)	Cross-sectional	U: 15	NS	-	-	NS	-	-	NS	-	-	0.037 (U↑)	-	-
		T: 56												
Pasquali (32)	Cross-sectional	U: 21	-	-	NS	-	-	NS	-	-	NS	-	-	NS
		T: 48												
Jiang-feng (33)	Longitudinal retrospective	39	NS	-	-	NS	-	-	NS	-	-	NS	-	-
Selice (34)	Longitudinal prospective	121*	<0.05 (U↑)	NS	-	NS	NS	-	-	-	-	NS	NS	-
Jørgensen (35)	Cross-sectional	U: 21	0.04 (U↓)	NS	-	NS	NS	-	-	-	-	0.01 (U↑)	NS	-
		T: 41												
Chang (2)	Cross-sectional	U: 23	0.007 (U↓)	-	0.003 (T↑)	NS	-	NS	-	-	-	0.002 (U↑)	-	0.001 (T↓)
		T: 50												
ZITZMANN (36)	Cross-sectional	U: 35	NS	-	-	-	-	-	NS	-	-	<0.05 (U↑)	-	-
		T: 97												

U = untreated KS, T = treated KS, C = controls, U↓ = lowest value in untreated KS, U↑ = highest value in untreated KS, T↑ = highest value in treated KS, NS = not significant.

*56 KS were treated and followed.

Table 3

	Wu et al. (1982)	Yoshida et al. (1997)	Raboch et al. (2003)	El et al. (2016)	Corona et al. (2009)	Skakkebaek et al. (2017)
Design	double blind cross-over with oral testosterone undecanoate	cross-sectional case control	cross-sectional case-control	cross-sectional case control	cross-sectional case control	cross-sectional case-control
Participants (mean age ± SD) or (median [range])	4 KS (35.3 ± 8.5)	40 KS (32.2 ± 4.0) 55 controls (33.5 ± 4.2)	77 KS (31 ± 5.78) 85 controls (32.7 ± 6.31)	53 KS (33 [26 - 40]) 75 controls (34 [30 - 39])	23 KS (40.6 ± 12.3) 1356 controls (51.7 ± 13.0)	132 KS (41.7 [19.0-76.5]) 313 controls (42.5 [17.0-77.2])
Reason for medical consultation	Infertility	Infertility	Infertility	Infertility	Sexual dysfunction	KS recruited from endocrine, genetic and fertility clinics Controls recruited from the male background population
Testosterone treatment	No treatment	NA	NA	NA	NA	95 KS received

	(min. 8 weeks)					testosterone
						36 KS no testosterone
						1 unknown
Sexual debut	-	-	-	-	-	Significant later
Number of sex partners	-	-	-	-	-	NS
Frequency of intercourse/week	4.5 (1.4)	Significant increased 4.4 (2.8)/month	NS	-	NS	NS
Orgasmic function	-	Decreased in 20 % of KS	-	-	-	Significant decreased
Sexual desire	Frequency of sexual thoughts /week 2.5 (0.4)	Decreased in 10 % of KS	-	Significant lower (Decreased in 55 % of KS vs. 17 % of C)	NS Decreased in 61 % of KS	NS
Erectile dysfunction		Increased in 2.5 % of KS	-	NS (Prevalence: KS 19%)	NS (Prevalence of severe ED: KS 23 %)	Significantly increased
Premature ejaculation	-	Prevalence of premature or delayed ejaculation: KS 57.5 %	-	Significant lower (Prevalence: KS 23 %)	NS (Prevalence: KS 9.5%)	NS Prevalence: KS 65 %, C
Delayed ejaculation	-		-	NS (Prevalence: KS 7.5 %)	NS (Prevalence: KS 9.5 %)	Significantly more often (Prevalence: KS 43 %)
Perceived Ejaculation volume	-	Decreased in 42.5 % of KS	-	-	Decreased in 62 % of KS	-
Testicular pain	-	-	-	-	-	Significantly more often (Prevalence: KS 23 %)

NA – not applicable

Table 4. Testosterone preparations available for treatment in Klinefelter syndrome and suggested doses for adults

Substance	Brand name (company)	Format	Route of administration	Suggested dose
Testosterone	Tostran® (Kyowa Kirin, Galashiels, UK)	Gel	Skin	20-70 mg per day
Testosterone	Testim® (Ferring, Saint-Prex, Switzerland)	Gel	Skin	50 mg per day
Testosterone	Testogel® (Bayer, Leverkusen, Germany)	Gel	Skin	50 mg per day
Testosterone undecanoate	Nebido® (Bayer, Leverkusen, Germany)	Injection	Intramuscular	1000 mg every 10-14 weeks
Testosterone undecanoate	Andriol® (MSD, Kenilworth, USA)	Capsule	Oral	120-160 mg per day in 2-3 doses
Testosterone enanthate	Testoviron® (Bayer, Leverkusen, Germany)	Injection	Intramuscular	250 mg every 2-4 weeks
Testosterone	Androderm® (Allergan, Parsippany, USA)	Transdermal patch	Skin	2.5-7.5 mg per day
Testosterone	Axiron® (Lilly, Indianapolis, USA)	Gel	Skin - axilla	30-60 mg per day

For children and adolescents, lower doses should be given (37). Some preparations are not available in all countries.

Table 5. Suggested treatment and intervention strategies in Klinefelter syndrome

Childhood and early adolescence:
Pedagogical supervision, including guidance on educational and lifestyle issues
Psychological referral if necessary
Information about support and peer groups
Puberty:
Consider supplementation of testosterone
Pedagogical supervision, including guidance on educational and lifestyle issues
Psychological referral if necessary
Information about support and peer groups
Adulthood:

Testosterone supplementation for most
Prevention of lifestyle diseases, including type 2 diabetes, obesity, chronic obstructive lung disease
Neurocognitive treatment
Fertility treatment
Estimation of bone density – DEXA scan
Information about the syndrome, including support and peer groups
Questions about well-being, physical activity, energy, sexual activity, libido

Reference List

1. **Smyth CM, Bremner WJ** 1998 Klinefelter syndrome. *Arch Intern Med* 158:1309-1314
2. **Chang S, Skakkebaek A, Trolle C, Bojesen A, Hertz JM, Cohen A, Hougaard DM, Wallentin M, Pedersen AD, Ostergaard JR, Gravholt CH** 2015 Anthropometry in Klinefelter syndrome - multifactorial influences due to CAG length, testosterone treatment and possibly intrauterine hypogonadism. *J Clin Endocrinol Metab* 100:E508-E517
3. **Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E** 2004 Klinefelter's syndrome. *Lancet* 364:273-283
4. **Aksglaede L, Skakkebaek NE, Almstrup K, Juul A** 2011 Clinical and biological parameters in 166 boys, adolescents and adults with nonmosaic Klinefelter syndrome: a Copenhagen experience. *Acta Paediatr* 100:793-806
5. **Bojesen A, Kristensen K, Birkebaek NH, Fedder J, Mosekilde L, Bennett P, Laurberg P, Frystyk J, Flyvbjerg A, Christiansen JS, Gravholt CH** 2006 The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. *Diabetes Care* 29:1591-1598
6. **Bojesen A, Birkebaek N, Kristensen K, Heickendorff L, Mosekilde L, Christiansen JS, Gravholt CH** 2011 Bone mineral density in Klinefelter syndrome is reduced and primarily determined by muscle strength and resorptive markers, but not directly by testosterone. *Osteoporos Int* 22:1441-1450
7. **van den Bergh JP, Hermus AR, Spruyt AI, Sweep CG, Corstens FH, Smals AG** 2001 Bone mineral density and quantitative ultrasound parameters in patients with Klinefelter's syndrome after long-term testosterone substitution. *Osteoporos Int* 12:55-62
8. **Fricke GR, Mattern HJ, Schweikert HU, Schwanitz G** 1984 Klinefelter's syndrome and mitral valve prolapse. an echocardiographic study in twenty-two patients. *Biomed Pharmacother* 38:88-97
9. **Andersen NH, Bojesen A, Kristensen K, Birkebaek NH, Fedder J, Bennett P, Christiansen JS, Gravholt CH** 2008 Left ventricular dysfunction in Klinefelter syndrome is associated to insulin resistance, abdominal adiposity and hypogonadism. *Clin Endocrinol (Oxf)* 69:785-791
10. **Bojesen A, Juul S, Birkebaek NH, Gravholt CH** 2006 Morbidity in Klinefelter syndrome: a Danish register study based on hospital discharge diagnoses. *J Clin Endocrinol Metab* 91:1254-1260
11. **Bojesen A, Juul S, Birkebaek N, Gravholt CH** 2004 Increased mortality in Klinefelter syndrome. *J Clin Endocrinol Metab* 89:3830-3834
12. **Zoller B, Ji J, Sundquist J, Sundquist K** 2016 High Risk of Venous Thromboembolism in Klinefelter Syndrome. *J Am Heart Assoc* 5:e003567
13. **Swerdlow AJ, Higgins CD, Schoemaker MJ, Wright AF, Jacobs PA** 2005 Mortality in patients with Klinefelter syndrome in Britain: a cohort study. *J Clin Endocrinol Metab* 90:6516-6522
14. **Seminog OO, Seminog AB, Yeates D, Goldacre MJ** 2015 Associations between Klinefelter's syndrome and autoimmune diseases: English national record linkage studies. *Autoimmunity* 48:125-128

15. **Panimolle F, Tiberti C, Granato S, Semeraro A, Gianfrilli D, Anzuini A, Lenzi A, Radicioni A** 2016 Screening of endocrine organ-specific humoral autoimmunity in 47,XXY Klinefelter's syndrome reveals a significant increase in diabetes-specific immunoreactivity in comparison with healthy control men. *Endocrine* 52:157-164
16. **Sawalha AH, Harley JB, Scofield RH** 2009 Autoimmunity and Klinefelter's syndrome: when men have two X chromosomes. *J Autoimmun* 33:31-34
17. **Harlow TL, Gonzalez-Alegre P** 2009 High prevalence of reported tremor in Klinefelter syndrome. *Parkinsonism Relat Disord* 15:393-395
18. **Koegl-Wallner M, Katschnig-Winter P, Pendl T, Melisch B, Trummer M, Holl E, Werner U, Schmidt R, Schwingenschuh P** 2014 Tremor associated with Klinefelter syndrome--a case series and review of the literature. *Parkinsonism Relat Disord* 20:323-327
19. **Swerdlow AJ, Schoemaker MJ, Higgins CD, Wright AF, Jacobs PA** 2005 Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. *J Natl Cancer Inst* 97:1204-1210
20. **Hultborn R, Hanson C, Kopf I, Verbiene I, Warnhammar E, Weimarck A** 1997 Prevalence of Klinefelter's syndrome in male breast cancer patients. *Anticancer Res* 17:4293-4297
21. **Ji J, Zoller B, Sundquist J, Sundquist K** 2016 Risk of solid tumors and hematological malignancy in persons with Turner and Klinefelter syndromes: A national cohort study. *Int J Cancer* 139:754-758
22. **Ratcliffe S** 1999 Long-term outcome in children of sex chromosome abnormalities. *Arch Dis Child* 80:192-195
23. **Lahlou N, Fennoy I, Ross JL, Bouvattier C, Roger M** 2011 Clinical and hormonal status of infants with nonmosaic XXY karyotype. *Acta Paediatr* 100:824-829
24. **Zinn AR, Ramos P, Elder FF, Kowal K, Samango-Sprouse C, Ross JL** 2005 Androgen receptor CAGn repeat length influences phenotype of 47,XXY (Klinefelter) syndrome. *J Clin Endocrinol Metab* 90:5041-5046
25. **Hasle H, Mellemgaard A, Nielsen J, Hansen J** 1995 Cancer incidence in men with Klinefelter syndrome. *Br J Cancer* 71:416-420
26. **Salbenblatt JA, Bender BG, Puck MH, Robinson A, Faiman C, Winter JS** 1985 Pituitary-gonadal function in Klinefelter syndrome before and during puberty. *Pediatr Res* 19:82-86
27. **van Rijn S, Aleman A, Swaab H, Kahn R** 2006 Klinefelter's syndrome (karyotype 47,XXY) and schizophrenia-spectrum pathology. *Br J Psychiatry* 189:459-461
28. **Stewart DA, Netley CT, Park E** 1982 Summary of clinical findings of children with 47,XXY, 47,XYY, and 47,XXX karyotypes. *Birth Defects Orig Artic Ser* 18:1-5
29. **van Rijn S, Swaab H, Aleman A, Kahn RS** 2008 Social behavior and autism traits in a sex chromosomal disorder: Klinefelter (47XXY) syndrome. *J Autism Dev Disord* 38:1634-1641
30. **Ross JL, Roeltgen DP, Kushner H, Zinn AR, Reiss A, Bardsley MZ, McCauley E, Tartaglia N** 2012 Behavioral and social phenotypes in boys with 47,XYY syndrome or 47,XXY Klinefelter syndrome. *Pediatrics* 129:769-778
31. **Yesilova Z, Ozata M, Oktenli C, Sanisoglu SY, Erbil MK, Dagalp K** 2004 Effect of supraphysiologic doses of testosterone on fasting plasma total homocysteine concentrations in men with Klinefelter's syndrome. *Fertil Steril* 81:1278-1282
32. **Pasquali D, Arcopinto M, Renzullo A, Rotondi M, Accardo G, Salzano A, Esposito D, Saldamarco L, Isidori AM, Marra AM, Ruvoilo A, Napoli R, Bossone E,**

Lenzi A, Baliga RR, Sacca L, Cittadini A 2012 Cardiovascular abnormalities in Klinefelter Syndrome. *Int J Cardiol* 168:754-759


33. **Jiang-Feng M, Hong-Li X, Xue-Yan W, Min N, Shuang-Yu L, Hong-Ding X, Liang-Ming L** 2012 Prevalence and risk factors of diabetes in patients with Klinefelter syndrome: a longitudinal observational study. *Fertil Steril* 98:1331-1335


34. **Selice R, Caretta N, Di MA, Torino M, Palego P, Ferlin A, Foresta C** 2013 Prostate volume and growth during testosterone replacement therapy is related to visceral obesity in Klinefelter syndrome. *Eur J Endocrinol* 169:743-749


35. **Jorgensen IN, Skakkebaek A, Andersen NH, Pedersen LN, Hougaard DM, Bojesen A, Trolle C, Gravholt CH** 2015 Short QTc Interval in Males with Klinefelter Syndrome-Influence of CAG Repeat Length, Body Composition, and Testosterone Replacement Therapy. *Pacing Clin Electrophysiol* 38:472-482


36. **Zitzmann M, Bongers R, Werler S, Bogdanova N, Wistuba J, Kliesch S, Gromoll J, Tüttelmann F** 2015 Gene expression patterns in relation to the clinical phenotype in Klinefelter syndrome. *J Clin Endocrinol Metab* 100:E518-E523


37. **Rogol AD, Tartaglia N** 2010 Considerations for androgen therapy in children and adolescents with Klinefelter syndrome (47, XXY). *Pediatr Endocrinol Rev* 8 Suppl 1:145-50.:145-150














Cognitive phenotype:

- IQ slightly below average
- Verbal impairments
- Memory impairments
- Auditory processing deficiencies
- Executive impairments
- Delayed social development

Personality profile:

Reserved, passive, unassertive, less talkative, less energetic, tendency to experience negative feelings, emotional arousal, impulsiveness, difficulties in approaches to new events, less organized, less self-disciplined, helpful, friendly

Psychiatric comorbidity:

- Depression
- Anxiety
- Autism spectrum diseases
- Attention deficit/hyperactivity disorders
- Schizophrenia

